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CHAPTER I. GENERAL INTRODUCTION 
1.1. Properties of GHB 
1.1.1. Chemistry and natural occurrence 
Gamma-hydroxybutyric acid and its sodium salt gamma-hydroxybuty-
rate-Na (GHB) are short chain (4-carbon) fatty acid structure analogues 
(Saytzeff, 1874), just as the putative neurotransmitter substance, gam-
ma-aminobutyric acid (GABA) (fig.l.l.). GHB is synthesized from its 
cyclic congener, gamma-butyrolactone (GEL), by alkaline hydrolysis 
(Chanlaroff, 1884). 
a- OXOGLUTARIC ACID 
GLUTAMIC ACID 
1 
CH 2 -CH 2 -CH 2 -COOH I 
NH 2 
4' -AMINOBUTYRIC 
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Fig. 1.1. Metabolic interrelationship between gamma-hydro-
xybutyric acid and other exogenous and endogenous compounds 
in brain (after Roth and Giarrnan, 1969). 
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The natural occurrence of GHB in mammalian brain was first pro-
posed by Wolf (1960) and Bessman and Fishbein (1963), but final evi-
dence was only obtained with the use of more sensitive techniques such 
as gas chromatography (Roth and Giannan, 1970). Thus far, GHB has 
been found to be present in the brains of the pigeon (Bessman and 
Fishbein, 1 963), cow and cat (Roth and Giannan, I 970), rat (Bessman 
and Fishbein, 1963; Roth and Giarman, 1970; Doherty et al., 1975 a), 
guinea pig (Roth and Giarman, 1970; Doherty et al., 1976), rabbit 
(Doherty et al., 1975 a) and man (Bessman and Fishbein, 1963). Highest 
concentrations in the guinea plg brain were observed in the hippocam-
pus, midbrain, diencephalon and cerebellum (Roth, 1970). 
GHB was reported to be synthesized in vivo from GABA via succinic 
semialdehyde (Roth and Giarman, 1969; Roth, 1970) (fig. 1.1.). There-
verse reaction, namely direct conversion of GHB to GABA, was proposed 
as the fate of GHB administered to the rat (Della Pietra et al., 1966) 
or mouse (De Feudis and Collier, 1970) and in rat brain tissue in vitro 
(Mitoma and Neubauer, 1968). Later reports have shown, however, that 
exogenous GHB is converted, in vivo, to succinate and thus enters into 
the tricarboxylic acid cycle (Doherty et al., 1975 b; MOhler et al., 
1976) (fig. 1.1.). 
GHB, GEL and some other structural analogues like 1 ,4-butanediol, 
appeared to have similar effects when injected into animals (Sprince, 
1969; Marcus et al., 1976). GHB seems to be the active form and GEL 
and 1,4-butanediol probably act only after their conversion to GHB in 
vivo (Roth and Giarman 1966; 1968) (fig. 1.1.). 
1.1.2. Sedative effects 
In a study on the antibiotic effects of saturated and unsaturated 
lactones, Giarman (Giacomino) and his co-workers noted that butyrolac-
tone, apart from exerting a positive therapeutic effect against influ-
enza virus in mice (200 mg/kg) (Rubin and Giarman, 1947), demonstrated 
complete suppression of cortical EEG activity and respiratory failure 
at a slightly higher dose (545 mg/kg), while, after 300 mg/kg, the res-
piratory rate was half the initial value (Giacomino and Me Cawley, 
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1947). 9 Years later it was reported that neutralized salts of short 
chain fatty acids, among them butyrate, induced 11unconsciousness" (loss 
of righting reflex) in rats, dogs, guinea pigs, mice, frogs and chicks 
(Samson and Dahl, 1955; Samson et al., 1956); in rabbits, drowsy behav-
ior was accompanied by a high amplitude, low frequency EEG (White and 
Samson, 1956). The only hydroxylated butyrate tested in these experi-
ments, beta-hydroxybutyrate, did not change the behavior nor the EEG 
pattern of the animals (Hhite and Samson, 1956; Scnnson et al., 1956). 
The authors regarded the butyrate-induced EEG as being similar to that 
seen during sleep and anesthesia (White and Samson, 1956), but the am-
plitude was higher than one would expect during physiological sleep or 
anesthesia. 
In the search for a structural analogue of GABA able to cross the 
blood-brain-barrier, Jouany and co-workers synthesized, among other 
gamma-substituted butyrates, the hydroxylated product, gamma-hydroxybu-
tyrate (sodium salt) (GHB) and reported its sedative action (Jouany et 
al., 1960 a,b). Injection of 500 mg/kg GHB in rats and non-restrained 
dogs induced an inhibition of the righting reflex, upon turning them on 
their side, for about 45 min; the authors considered this as sleep 
(Jouany et al., 1960a,b). In the rabbit, a slightly higher dose was need-
ed to induce the same effect (Jouany et al., 1960 b). Similar results 
were obtained with GEL in the rat, pigeon and rabbit (Benda and Perles, 
1960). In the cat, 500 mg/kg GHB induced a high amplitude, slow wave 
electroencephalogrcnn (EEG) (Jouany et al., 1960 b). These authors also 
reported that GHB (500 mg/kg in rat) postponed the convulsive and le-
thal effects of pentylenetetrazole, isoniazide and strychnine and, in 
the cat, it antagonized the hydroquinone-induced tremor and epileptic 
EEG. 
The first experiments with GHB on humans were conducted by Laborit 
(Laborit et al., 1960). The dose required to induce a sedative state 
("sleep 11 ) in man was much lower than in animals (60 mg/kg). Twenty mi-
nutes after administration of GHB, high amplitude, slow waves appeared 
in the EEG, but behavioral sedation was visible only after another 10-
15 min. On the basis of this sedative action, these authors started to 
use GHB for inducing surgical anesthesia, although they described the 
effect of GHB as 11physiological sleep, both clinically and electroen-
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cephalographically" (Laborit et al., 1960). It was established that a 
premedication (generally pethidine and promethazine) was indispensible 
in order to obtain a stable anesthesia. However, with the correct pre-
medication, GHB induced a state of anesthesia after a latency period of 
10-20 min, which was accompanied by a slowing of the heart and respira-
tion rate, muscular relaxation and myosis of the pupils. The duration 
of the anesthesia was dependent on the dose of GHB administered. When 
the effect of GHB ended, consciousness reappeared abruptly, accompanied 
by a sensation of pain. The authors initially reported the successful 
use of GHB-induced anesthesia in 40 cases of various kinds of opera-
tions (Laborit et al., 1960). Thereafter, GHB was used in neuroradio-
graphy and neurosurgery (Laborit et al., 1961) and ~n a wide variety of 
other types of operations (Blumenfeld et al., 1962; Solway and Sadove, 
1965; and many other reports). 
The sedative state induced by GHB, without premedication, was not 
a total anesthesia, because it was not possible to apply a surgical 
stimulus without producing reflex movements (Helrich et al., 1964). 
Hence, because of the induced state of unconsciousness accompanied by 
a high amplitude slow wave EEG and the possibility of inducing both be-
havioral and electrocortical arousal, when sufficiently strong stimuli 
were applied, many authors referred to the GHB-induced state as sleep 
(for references, see Perez de la Mora and Tapia, 1970; Laborit, 1973). 
There has been some discussion as to wether sleep observed after 
injection of GHB is induced by this compound itself or by a metabolite. 
In man the maximal sedative effect lagged behind the peak blood level 
of GHB (Helrich et al., 1964) whereas in rats sleep induced after the 
administration of GHB appeared simultaneously with the concomitant peak 
in GEL concentration in the brain and blood (Bessman and Skolnik, 
1964). Furthermore, the effective dose of GEL was lower than that of 
GHB (Bosko and Gluckman, 1963). It was, thus, concluded that GBL was 
the active compound (Bessman and Skolnik, 1964). Shortly aftenvards, 
however, Giarman and Roth (1964) reported the rapid conversion of GBL 
to GHB by a lactonase in the rat ~n vivo (Giarman and Roth, 1964) and 
in rat, cat and human blood and rat liver in vitro (Roth and Giarman, 
1966). Therefore, they suggested that GHB was the active form. They 
also noted that GEL was inactive, when injected intra-cisternally in 
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the rat, or into the thalamus or hippocampus in the monkey, whereas 
GHB, administered along these routes, induced behavioral depression or 
a high amplitude EEG, respectively (Roth et al., 1966). This was ex-
plained by the absence of the lactonase metabolizing GBL in brain tis-
sue, confirming the suggestion that GBL has to be metabolized to GHB 
in the blood before it can act. These authors also noted a high con-
centration of GBL in muscle tissue shortly after its intravenous ad-
ministration (Roth and Giarman, 1966). They suggested that GBL, being 
non-polarized, is taken up more rapidly into muscle tissue than is the 
polarized GHB, and is only released slowly into the blood. This might 
explain the longer duration of action of GBL compared to GHB after in-
travenous administration, and also the lack of difference after intra-
peritoneal injection of these compounds, because then both are only 
released slowly into blood (Roth and Giarman, 1966). 
1.1.3. Paradoxical sleep 
Behaviorally, two states of vigilance can be distinguished in ani-
mals and man: wake and sleep. Electroencephalographically, the awake 
state is characterized by fast, low amplitude or 11 desynchronized 11 
waves, whereas during sleep the electroencephalogram (EEG) shows slmv, 
high amplitude ( 11 synchronized 11 ) waves, interrupted, paradoxically, by 
desynchronized EEG activity as seen during wake (Klaue, 1937; Dement 
and Kleitman, 1957; Jouvet et al., 1959). 
In man, rapid movements of the eyeballs were observed during be--
havioral sleep associated 'tVith desynchronized EEG; when the subjects 
\Vere awakened during a period of rapid eye movements, they very often 
recalled having dreamed (Aserinsky and Kleitrnan, 1953; Dement and 
Kleitman, 1957). The muscular tone, already low during behavioral 
sleep associated with synchronized EEG, disappeared totally during the 
desynchronized phase of the sleep state (Jouvet et al., 1959), which 
enables differentiation to be made between the latter phase and the 
awake state, by means of the electromyogram (EMG) in combination with 
the EEG. 
In view of these differences, the behavioral sleep state was di-
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vided into two separate phenomena (Dement, 1958; Jouvet et al., 1959), 
which have been named according to the parameter thought to be most 
characteristic f0r each phenomenon. Thus, on the basis of the EEG, 
the sleep state characterized by slow, high amplitude waves has been 
called slow wave sleep (SWS) or synchronized sleep, to differentiate 
it from desynchronized or fast wave sleep. Because of the paradoxical 
appearance, during behavioral sleep, of a desynchronized EEG, charac-
teristic of the active waking state, the desynchronized sleep state has 
also been called active or paradoxical sleep (PS). The obvious paral-
lel of PS, orthodox sleep, has rarely been used as a synonym for SWS. 
On the basis of the occurrence of rapid eye movements during PS, this 
state has been designated REM sleep, as opposed to non-REM for SWS. 
Because the arousability during PS is lower than during SWS, the names 
deep and light sleep, respectively, have been introduced. The occur-
rence of dreams during PS, which of course can only be observed in man, 
gave rise to the use of the name dream sleep. Starting from the ana-
tomical structure thought to be responsible for the triggering of PS, 
the rhombencephalon, this state has also been called -mainly in French 
literature- "phase rhombencephalique du sommeil". We will use here the 
names SWS and PS, because they are most commonly used in the litera-
ture, at least as concerned to the rat. 
Other phenomena observed during PS, are a regular 6-8 Hz rhythm in 
the hippocampal EEG, and monophasic peaks in EEG derivations from the 
pontine reticular formation (Jouvet et al., 1959), the lateral genicu-
late nucleus (Mikiten et al., 1961) and the occipital cortex (Mouret et 
al., 1963); these were called PGO-spikes. 
The first experiments, leading to the discrimination between SWS 
and PS, were carried out in cats, rabbits and man. Later experiments 
showed that these sleep stages could also be distinguished in rats 
(Michel et al., 1961; Roldan and Weiss, 1962; Swisher, 1962). Most be-
haviOral and electrographical phenomena characterizing PS in the cat 
were also observed in the rat, except PGO-spikes, which are absent in 
this species (Stern et al., 1974). 
Intraperitoneal (i.p.) administration of GHB and GBL in low doses 
(50-100 rng/kg) was reported to induce PS in intact cats (Jouvet et al., 
1961; Matsuzaki et al., 1964) and decorticate cats (Jouvet et al., 
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1961). Sodium butyrate also induced PS in cats, when injected intrave-
nously (i.v.) (Matsuzaki et al., 1964; Matsuzaki and Takagi, 1967 a) 
but not when injected i .p. (Matsuzaki and Takagi, 1967 a). Sodium 
butyrate induced PS in various cat brain-stem preparations as well 
(Matsuzaki and Takagi, 1967 b). Delome et al., (1966) reported a sim-
ilar induction of PS in the mesencephalic cat following i.v. injection 
of 200 mg/kg GHB. The consistency of this effect depended on the point 
at which the injection was made in the sleep cycle, since a 15-20 mln 
"refractory period 11 was found to occur after a period of spontaneous 
PS. However, this was not confirmed by other authors (Vern and 
Hubbard, 1971). The latter authors also reported that true PS could be 
induced in cats, within 5 min of GHB administration (190 mg/kg i.v.), 
with only 9 out of 30 injections, whereas the rate of PS induction af-
ter control injections was 2 out of 30. Lower doses of GHB (40-100 
mg/kg i.v.) had similar effects (Vern and Hubbard, 1971). Other au-
thors either did not observe any PS in cats after i.v., i.p. or oral 
administration of 100 mg/kg GHB (Drakontides et al., 1962) or failed to 
observe a significant difference in periodicity or duration of PS after 
60 mg/kg GHB, injected i.p., in this species (Winters and Spooner, 
1965 a). Equivalent doses of GHB, GEL or butyrate, injected i.p. or 
i.v., failed to induce PS in rats (Marcus et al., 1967). Also, in 
chicks, PS was not induced by GHB (Osuide, 1972 b). Furthermore, PS 
was not induced in man after oral GHB (Metcalf et al., 1966) or i.v. 
GHB or GEL (Yamada et al., 1967). In human insomniacs, an increase in 
the amount of PS during the first third of the night was observed after 
administration of GHB, but the total PS per night was unchanged 
(Mamelak et al., 1973). 
1.1.4. EEG hypersynchrony 
Soon after the sedative effects of GHB and GEL were described and 
GHB came into use as an anesthetic adjuvant, it was reported that the 
EEG patterns, induced by these compounds in man, were different from 
those observed during physiological sleep or anesthesia (Benda et al., 
1960; Solway and Sadove, 1965). These GHB-induced EEG patterns in man 
were called "epileptogenic" because of their high <3D1plitude (Schneider 
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et al., 1963) and bear same similarity to the spike-wave complexes 
seen during absence (petit mal) epilepsy. Such high amplitude EEG pat-
terns are often called "hypersynchrony", referring to the excessive 
synchronization of the neuronal population which is discharging, thus 
causing the high amplitude (Gas taut and Tassinari, 1975). In some 
cases, GHB produced tremors and clonic ("epileptiform") movements after 
rapid induction of anesthesia; these phenomena could be blocked by bar-
biturates (Laborit et al., 1961). 
Large doses of GHB (about 1500 mg/kg) caused convulsions, with 
corresponding EEG effects, in rabbits (Cahn et al., 1960; Schneider et 
al., 1963) and chicks (Osuide, 1972 b), and caused convulsions in mice 
(Banet al., 1967). In cats, GHB prolonged the evoked seizure activity 
1n the hippocampus and amygdala (Drakontides et al., 1962). 
Winters and his collaborators were the first to specifically point 
out that the central effects produced by GHB in cats (Winters and 
Spooner, 1965 a,b; 1966) and by GHB, GBL and short chain fatty acids 
1n rats (Marcus et al., 1967) are epileptoid, rather than depressant, 
at all dose levels. They also pointed out that these non-convulsive 
epileptoid manifestations, appearing superficially as behavioral de-
pression, might be misinterpreted. They described the induction, in 
the cat, by 700 mg/kg GHB, of "a progression of several types of epi-
leptiform EEG patterns", ranging from intermittant hypersynchrony via 
continuous hypersynchrony to polyphasic bursts (i.e. bursts consisting 
of positive and negative spikes) with intermittent cortical silence. 
Thereafter the EEG passes through the same states in the reverse order 
until its final return to normal (Winters and Spooner, 1965 b). In the 
rat a similar sequence of EEG patterns was observed after 700 mg/kg 
GHB, with one difference: the continuous hypersynchrony consisted of 
two periods: first 2!-3 c/s waves appeared and thereafter the frequen-
cy was reduced to 1-2 c/ s (Marcus et al., 1967). Lower doses of GHB 
(200-600 mg/kg in cat or 250 mg/kg in rat) showed the same progression 
of EEG phenomena, though without the phase of polyphasic bursts with 
intermittent cortical silence (Winters and Spooner, 1965 a; Marcus et 
al., 1976). Recently, it was established that these changes in EEG 
pattern correlate well with the serum level of GHB (Snead et al., 
1976). 
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During the continuous hypersynchrony and polyphasic bursts with 
intermittent cortical silence, the animals show a loss of righting re-
flex, and this is the phenomenon which lead other authors to refer to 
this state as "sleep". It was noted that the continuous EEG hypersyn-
chrony in the cat shows similarities to the 3 c/s spike-and-wave pat-
tern, characteristic for human absence epilepsy (Snead et al., 1976). 
Low doses did not induce convulsive or jerky movements, but following 
doses of 600 mg/kg GHB or higher, spontaneous and auditory stimulation-
induced myoclonic movements were observed in cats (Winters and Spooner, 
1965 a,b), rats (Marcus et al., 1967) and chicks (Osuide, 1972 b). 
Moreover, repetitive auditory stimuli in cats induced typical tonic-
clonic convulsions, accompanied by hypersynchronous, high frequency EEG 
seizures (Winters and Spooner, 1965 b). GHB also enhanced the cortical 
evoked response induced by acoustic stimulation in cats (Winters and 
Spooner 1965 a) and rats (Kharkevich et al., 1971; Borbely and Huston, 
1973), and photic stimulation and stimulation of the sciatic nerve in 
rats (Kharkevich et al., 1971). 
From these observations, it was concluded that the phenomena in-
duced by GHB are excitatory rather than depressive (Winters and 
Spooner, 1965 a; Marcus et al, 1967). This formed a part of the basis 
for a new theory concerning a continuum of excitatory states, anesthe-
sia, hallucinosis and epileptic phenomena (Winters, 1976). It has also 
been proposed that GHB, because of its excitatory properties, might be 
used as an activating drug for clinical EEG diagnosis (Hirata et al., 
1973). 
The synthetic compound, I-hydroxy-3-amino-pyrrolidone-2 (HA-966), 
is chemically related to the cyclic anhydric form of GABA and is thus 
a structure analogue of GHB and GBL (Havinga, Roorda and Kerling, 1959, 
uepublished). When injected into rats, rabbits and monkeys, HA-966 
induced a sedative state and EEG hypersynchrony, which were similar to 
the phenanena induced by GHB and GEL (Bonta et al., 1971). 
I .I .5. Dopaminergic neurotransmission 
Gessa and his co-workers showed that administration of GHB, as wcll 
as GBL and I ,4-butanediol, both of which are converted in vivo to GHB 
(Roth and Giarman, 1966;1968), produced a selective, dose-dependent in-
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crease ln brain dopamine (DA) concentration (Gessa et al. ,1966), with 
little or no effect on levels of other brain monoamines such as nor-
adrenaline, serotonin or GABA (Giarman and Schmidt, 1963; Gessa et al., 
1966; 1968). Fluorescence histochemistry has shown that the increased 
DA is located in "dots" in the nerve endings in brain areas that are 
also known to have a high DA content in control animals (e.g. nucleus 
caudatus, nucleus accumbens and tuberculum olfactorium) (Aghajanian and 
Roth, 1970). Recently, it has been found that, in the median eminence, 
though it is an area rich in DA, GEL does not induce increased DA lev-
els (Gudelsky and Moore, !976). 
It was also established that GHB is not likely to act via inhibi-
tion of the metabolism of DA, since GHB does not affect the enzymes 
monoamine-oxidase (MAO) and catechol-0-methyl transferase (COMT), 
which are responsible for DA-breakdown (Gessa et al., 1968), and because 
of the fact that the increased DA-induced fluorescence after GHB admin-
istration has a different appearance (dotted) from the increased DA 
fluorescence (diffuse) caused by the MAO inhibitor pargyline (Aghajanian 
and Roth, 1970). It was demonstrated that the rise in DA concentration 
was, at least in part, dependent on de novo synthesis of this neuro-
transmitter, since inhibition of DA-synthesis by alpha-methyl-para-ty-
rosine (AMPT) prevented the increase in DA after GHB (Gessa et al., 
1968). However, the decrease in DA level observed by Roth and Suhr af-
ter AMPT treatment was increased to control levels (but not higher) by 
the GHB p-recursor GBL. They suggested, therefore, that the increase in 
DA was caused, not only by increased synthesis, but also by decreased 
utilization or release of this compound (Roth and Suhr, 1970). The 
GHB-induced behavioral sedation, however, was not suppressed when AMPT 
inhibited the GHB-induced DA-increase (Gessa et al., 1968; Roth and 
Suhr, 1970). In fact, it was even significantly prolonged (Roth and 
Suhr, 1970). This might suggest that increased DA synthesis is not es-
sential, at least, for inducing sedation. 
GHB did not change the effects of AMPT on noradrenaline-containing 
neurons, once again indicating that GHB acts specifically on DA neurons 
(Gessa et al., 1968; Roth and Suhr, 1970). Moreover, GBL caused a se-
lective increase in the specific activity of brain dopamine, but not of 
noradrenaline, when rats were injected with radiolabelled tyrosine 
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(Roth and Suhr~ 1970). This selective action of GHB on newly synthe-
+ 
sized DA was also confirmed by the ability of GHB to antagonize K -
induced release of 3H-dopamine from brain slices incubated with 3H-ty-
rosine, but not when incubated with 3H-DA; nor did GHB antagonize the 
release of 3H-5-hydroxytryptamine after incubation with 3H-tryptophan 
(Bustos and Roth, I 972). More important, however, was the indication, 
obtained from these results, that GHB might act via inhibition of DA-
release. 
Similar phenomena as those mentioned above, induced by GHB in 
whole brain (e.g. increased DA level, higher specific activity of DA 
after injection of 3H-tyrosine together with GBL), were also observed 
in the rat corpus striatum (nucleus caudatus-putamen), a brain area 
rich in DA nerve terminals (Walters and Roth, 1972). This directed 
most further research efforts, concerning the mechanism of action of 
GHB on DA neurotransmission, towards the rat striatum. 
Two groups of researchers simultaneously compared the effect of 
GHB with the results of hemisection (axotomy) of the nigra-striatal DA 
neurons. These manipulations exhibited several striking similarities: 
a rise in DA level; deceleration of AMPT-induced DA disappearance 
(Stock et al., 1973; Walters et al., 1973); blockade of the increase in 
DA concentration by intrastriatal injection of 25/o KCl (Stock et al., 
1973); increased DA fluorescence in the striatal nerve terminals on the 
lesioned side (Walters et al., 1973). This suggested that inhibition 
of neuronal impulse flow was the main cause of the GHB-induced rise in 
DA level. The most convincing evidence in this direction was supplied 
by Walters and her co-workers, who showed that GHB inhibited the firing 
rate of the dopaminerg~c neurons in the substantia nigra zona compacta, 
sending their axons to the striatum (Walters et al., 1972). Though a 
rise in DA level in rat brain was observed only after administration 
of GHB in doses higher than 750 mg/kg and was maximal after 1500 mg/kg 
(Stock et al., 1973), even a dose as low as I 00 mg/kg GHB or GBL was 
sufficient to decrease the firing rate of nigral DA cells (Roth et al., 
I 973). 
Starting from the premise that the inhibition of impulse flow was 
the main effect of GHB, these authors developed a theory explaining the 
simultaneous rise in DA level in terms of a sensitivity of tyrosine 
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hydroxylase to Ca++ ions. This theory stated that if, after inhibition 
of the impulse flow, the normal influx of Ca ions into the nerve ending 
is decreased, the tyrosine hydroxylase might change into a conformation 
for which the critical level of DA, necessary to inactivate the enzyme, 
is increased (Roth et al., 1974). The resulting enhanced DA synthesis, 
together with the cessation of the release, might thus be responsible 
for the increased DA concentration. Further evidence for the role of 
the impulse flow was produced recently when the GEL-induced increase in 
striatal DA was antagonized by electrical stimulation of the nigra-
striatal pathway (Murrin and Roth, 1976). 
The mechanism by which GHB induces inhibition of the impulse flow 
is not yet clear. Based on the facts that administration of GHB or 
GABA directly into the substantia nigra enhances striatal DA levels 
(Anden and Stock, 1973), that microiontophoresis of GABA produces inhi-
bition of the firing rate of nigral neurones (Feltz, 1971), and on the 
structural similarity between GHB and GABA, it has been suggested that 
GHB acts synergistically with the action of putative inhibitory GABA-
ergic nerve terminals in the substantia nigra (Anden and Stock, 1973). 
Another proposed mechanism for GHB in inducing an increase in striatal 
DA should be mentioned, namely an action on the storage granule mem-
brane, for which the integrity of these granules is necessary (Menon et 
al. , I 97 4) . 
A possible causal relationship between the effects of GHB or GEL 
on DA brain levels or neurotransmission on the one hand and GHB- or 
GEL-induced behavioral sedation on the other, has been discussed by 
several authors. Some of the arguments were: 
(a) a good temporal correlation was obtained between the sedative ac-
tion and the accumulation of brain DA after GHB administration in 
rabbits (Gessa et al., 1966; Walters and Roth, 197 2); 
(b) when GHB was injected into different brain areas in unanesthetized 
cats, the striatum, an area with high DA levels, was most sensitive 
to the actions of this drug (Gessa et al., 1967); 
(c) AMPT acts synergistically with GHB in the sense that when the re-
lease of DA 1s partly inhibited by GHB, the amount of DA available 
for release 1s diminished by AMPT. It appeared that AMPT increases 
the duration of GHB-induced sedation (Roth and Suhr, 1970); 
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(d) amphetamine prevented the GHB-induced increase in DA level, proba-
bly due to release of newly synthesized DA (Anden et al., 1973); 
this compound also reduces GHB-induced sedation (Roth and Suhr, 
1970). 
Hutchins and co-workers excluded a causal relationshlp between GHB-
induced sedation and DA-neurotransmission because they did not observe 
an increase in DA after GHB, when rats were pretreated with reserpine, 
but nevertheless sedation was induced (Hutchins et al., 1972). This 
might be due, however, to the relatively high dose of reserpine used 
(5 mg/kg), because a lower dose of reserpine (2 mg/kg), though deplet-
ing brain DA, did not prevent an increase in DA when followed by GHB 
(Gessa et al., 1968). 
The synthetic compound HA-966, similar to GHB in structure and in 
its hypersynchronizing effect on the EEG (see 1.1 .4), also exerts simi-
lar effects on dopaminergic neurotransmission. Intraperitoneal injec-
tion of HA-966 induced an increase in DA-concentration in the rat cor-
pus striatum (Bonta et al., 1971). The AMPT-induced DA-depletion was 
counteracted by HA-966 (Bonta et al., 1971) and the intraneuronally-
formed DA metabolite 3,4-dihydroxy-phenylacetic acid (DOPAC) was in-
creased in the striatum, whereas the level of the DA metabolite homo-
vanillic acid, which is dependent on the extraneuronally-located en-
zyme COMT, was increased (Hillen and Noach, 1971). These results sug-
gested an analogy to the effects of GHB, namely that HA-966 inhibits 
the release of DA in rat striatum (Hillen, 1972). Further experiments 
revealed that these effects of HA-966 are caused by inhibition of the 
impulse flow in the nigra-striatal DA neurons (VanValkenburg, 1976; 
Walters and Roth, 1976). 
1.1.6. GABA-synthesis 
GABA is synthesized in the brain by decarboxylation of glutamic 
acid, under the influence of the pyridoxal-phosphate-dependent enzyme, 
glutamic acid decarboxylase (GAD). 
GHB appeared to inhibit GAD activity in vivo, in the mouse brain 
(Clifford et al., 1973) and rat brain (Godin and Mark, 1967; 
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Tunnicliff, 1976), and ~n the mouse brain in vitro it inhibited GAD 
competitively (Dye and Taberner, 1975). GHB was not reported to change 
brain GABA concentration in these and most other studies (Giarman and 
Schmidt, 1963; Godin and Mark, 1967; Mitoma and Neubauer, 1968; 
Clifford et al., 1973; Tunnicliff, 1976), except two observations in 
which the GABA level was said to be elevated (Wolleman and Devenyi, 
1963; Della Pietra et al., 1966). However, one of these reports did 
not mention any significance in differences (Della Pietra et al., 
1966); the other only stated that there was induction of a "slightly 
increased GABA content of rat and rabbit brain", without any quantita-
tive evaluation (Wolleman and Devenyi, 1963). The latter authors, 
moreover, did not observe any change in GAD activity after GHB 
(Wolleman and Devenyi, 1963), which might be a consequence of the meth-
od used. It has also been noted that GHB induced an increased GAD ac-
tivity, accompanied by decreased glutamate levels (Promislov and 
Solovjova, 1973). 
HA-966 has been reported to inhibit GAD (Hillen et al., 1969) and 
decrease brain GABA concentration as well (MOhler et al., 1975). 
1.1.7. Effects on serotonin, acetylcholine and excitatory amino acids 
Administration of GHB (500 mg/kg) to mice induced an increase in 
the concentrations of the neurotransmitter substance serotonin, in 
whole brain (Benton et al., 1974) and brain stem (Clifford et al., 
1973). Other authors did not observe any change in brain levels of se-
rotonin (Giarman and Schmidt, 1963; Spano and Przegalinsky, 1973), but 
instead, increased synthesis and turnover rate of brain serotonin have 
been reported (Spano and Przegalinsky, 1973). It has not been estab-
lished whether these changes are related to increased neuronal activity 
or to serotonin release. 
Administration of GEL (750 mg/kg) increased acetylcholine concen-
trations in whole mouse brain, cortex and corpora quadrigemina (Giarman 
and Schmidt, 1963) and in whole rat brain, subcortex, striatum and, 
especially, hippocampus (Sethy et al., 1976). It was suggested that 
GHB inhibits the impulse flow in cholinergic neurons (Sethy et al., 
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1976), analogous to the effect on DA neurons (see 1.1.5.). No temporal 
correlation was obtained between the increase in acetylcholine and the 
depth of "anesthesia11 produced by GEL (Sethy et al., 1976). 
T~1e amino-acids 1-glutamate and 1-aspartate are putative excitato-
ry neurotransmitters. GHB has been reported to increase brain levels 
of both glutamate (Promislov and Solovjova, 1973) and aspartate 
(Margolis, 1969). On the other hand, inhibition of the biosynthesis 
of these compounds by GHB has also been observed (Godin and Mark, 
1967). 
I .1 .8. Anticonvulsive properties 
GHB has been reported to induce epileptoid EEG and behavioral phe-
nomena (see 1.1.4.) but, nevertheless, this compound antagonized con-
vulsions elicited by chemical and electrical stimuli. 
Pentylenetetrazol convulsions were antagonized by GHB in rats 
(Jouany et al., 1960 a), mice (Gluckman and Rosko, 1963), and chicks 
(Osuide, 1972 b), though other authors found no effect in mice and rats 
(Mayer, 1974). Strychnine convulsions were antagonized in rats (Jouany 
et al., 1960 a; Mayer, 1974) and mice (Banet al., 1967; Mayer, 1974), 
but in chicks GRB potentiated the convulsive effect of strychnine 
(Osuide, 1972 b). GHB antagonized convulsions elicited by isoniazide 
in rats (Jouany et al., 1960 a) and by picrotoxin in chicks (Osuide, 
1972 b). Semicarbazide convulsions were antagonized by GRB in mice 
(Banet al., 1967) while other authors observed no significant protec-
tion in mice (Gluckman and Rosko, 1963; Mayer, 1974) and rats (Mayer, 
1974). The doses of GRB, effective against these convulsant sub-
stances, were, as far as mentioned by the authors, 500 mg/kg in rodents 
(Banet al., 1967; Jouany et al., 1960 a; Mayer, 1974) and 680 mg/kg in 
chicks (Osuide, I 972 b). 
In mice, GRB antagonized electroshock convulsions (Gluckman and 
Rosko, 1963; Banet al., 1967) in a dose of 500 mg/kg, but a dose of 
300 mg/kg tended to increase the mortality rate (Banet al., 1967). 
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1.1.9. Tranquillizing properties 
GHB has been used successfully in the treatment of acute anxiety 
states in psychiatric patients (Du Couedic et al., 1964). In these 
experiments, GHB was administered in doses inducing a state of behav-
ioral sedation and thus GHB does not necessarily possess a specific anx-
iolytic effect. 
In mice, rats and cats, sub-sedative doses of GHB have been shown 
to decrease aggressive responses; it was concluded that GHB possesses 
specific tranquillizing properties (POschlova et al., 1974; Burov et 
al., 1976). 
I .I .10 Other effects 
GHB has been shown to block the uptake and accumulation of exoge-
nous noradrenalin in the rat vas defert;:ns but it had no effect on the 
level of the endogenous adrenergic mediator in this tissue (Arefolov 
and Panasyuk, 1975). At a dose of 1000 mg/kg, GHB has been reported to 
induce an increase in heart frequency and blood pressure in rats (Gomes 
et al., 1976), Administration of 400 mg/kg GEL to rats induced a tri-
phasic change in body temperature, consisting of a decrease, followed 
by an increase and another decrease, whereupon, after about 6 h, the 
normal temperature is restored (Borbely and Huston, 1972). 
Administration of GEL (500 mg/kg) to female rats, just prior to 
the proestrous critical period, significantly reduced serum LH and FSH 
levels and ovulation; it was suggested that these effects were mediated 
through inhibition of the neurotransmission in a central DA pathway 
(Beattie et al., 1976). 
GHB has been shown to increase brain glucose levels in mice (Godin 
et al., 1968; Leonard and Watkinson, 1971), probably by enhancing glu-
cose synthesis (Leonard and Watkinson, 1971). An increase in glucose-
6-phosphate dehydrogenase activity has also been noted after GHB 
(Taberner et al., 1972). 
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1.2. Aims 
In vlew of the reported sedative effects of GHB, to which many au-
thors referred as a "sleep like" state (see 1. 1. 2.), we decided to com-
pare the GHB-induced effects with natural sleep in the rat. Sleep was 
measured electrographically, using both EEG and EMG, in order to dif-
ferentiate between wake and the two sleep states: SWS and PS. Thus, it 
was also possible to determine whether GHB induces PS in rats, as ob-
served in cats (see I. 1.3.). It was established that administration of 
GHB, only in the doses lower than 100 mg/kg, was follmved by EEG pat-
terns similar to those observed in untreated animals. The effect of 
this dose range on the duration of the sleep stages was measured. 
In addition, we analyzed behavioral and electrographical phenomena 
induced by 200 mg/kg GHB. Since we observed that these phenomena are 
reminiscent of generalized, non-convulsive epilepsy or absence (petit 
mal) epilepsy in man, we investigated whether or not these effects could 
be antagonized with specific anti-absence drugs. 
In searching for a neurotransmitter system underlying the GHB-in-
duced EEG phenomena we subsequently examined whether or not modulation 
of DA (see 1.1.5.) and GABA neurotransmission (see 1. 1.6.) would affect 
these phenomena. 
1.3. Materials and methods 
1.3.1. Animals 
All experiments were carried out on non-restrained male Wistar 
rats, obtained from the animal breeding farm of TNO (Zeist, The 
Netherlands). 
1.3.2. Implantations 
Cortical electrodes were implanted when rats had reached the 
weight of 160-180 g. The animals were anesthetized with Hypnorm(R) (10 
mg fluanison and 0.2 mg fentanyl per ml; Philips-Duphar, Amsterdam, The 
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Netherlands) in doses of I.5 ml/kg, injected either intraperitoneally 
or subcutaneously into the neck or the flank. Two kinds of prepara-
tions were used: chronically (Chapter 2-7) and semi-chronically (Chap-
ter 8) implanted rats. 
1.3.2. I. Chronic electrodes 
When the rats ceased to respond to tactile stimuli, after Hypnorm 
injection, the skin over the skull was shaved and cleaned with 70% eth-
anol. The animals were then placed in a stereotactic apparatus and 
secured by ear-bars and an upper-incisor bar. A midline incision was 
made in the skin overlying the skull, fran between the eyes backward 
until a point over the neck muscles, about 2 em behind the skull. The 
uncovered periost was removed and then the nose-pressure-bar was fixed. 
The wound edges were drawn sidewards by small clamps and eventually af-
ter bleeding of the vessels in the bone was stopped, the skull was 
cleaned and dried with 70% ethanol. 
Next, holes of 0.8 mm diameter were drilled in the skull, into 
which the EEG electrodes would be placed. The placement of the holes 
was as follows: one hole was drilled about 4 mm anterior to the bregma 
(the intersection point of the sagittal and coronal sutures) and about 
I mm laterally to the sagittal suture; this hole served as the site for 
the reference electrode. Two holes were drilled bilaterally, about 
mm anterior to the coronal suture, or, in a few rats, about I mm poste-
rior to the coronal suture, and about 2.5 mm laterally to the sagittal 
suture; these holes were placed over the frontal cortex. Two other 
holes were made bilaterally over the parietal cortex, about 5 mm poste-
rior to the frontal holes and about 2.5 mm laterally to the sagittal 
suture. In a few rats, mentioned in Chapter 2, the holes on the right 
side were drilled as close as possible to the sagittal suture. 
If necessary, the skull was cleaned and dried again after drilling 
the holes and then silver, or stainless steel, screw electrodes were 
secured in the holes. The diameter of the screw-thread was 1 mm and 
the length 1.5 mm; its tip was rounded and rested on the dura mater. 
The diameter of the head was 1.5 mm. A length of insulated copper wire 
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(about 1.5 em) was soldered to the screw-head beforehand. The bone of 
the skull and the screws 
of dental acrylic cement 
were then covered 
(R) (Durelon , ESPE 
with an initial thin layer 
GmbH, Seefeld/Oberbay, W.-
Germany). This first layer was applied as early as possible in order 
to prevent bleeding during the further manipulations, which would oth-
erwise decrease the attachment of the cement to the bone. 
The copper wires from the screw electrodes were then soldered to 
an 8-pin miniature contact socket, to which two myogram electrodes were 
connected beforehand via insulated copper or stainless steel wire (fig. 
1.2.). The socket was fixed to the skull with another application of 
connector 
EMG electrode dental cement 
neck muscle 
Fig. I. 2. 
electrodes 
EEG electrode 
skull 
brain 
Schematic drawing of chronically implanted 
and contact socket in a rat. 
dental cement, covering the wires from the screw electrodes and with 
the wires to the myogram electrodes protruding from the posterior side. 
Then a small slit was torn in the two upper muscle layers on both sides 
of the neck, and at each side a myogram electrode was fixed, on the 
third muscle layer, with one or two stitches of surgical thread. The 
myogram electrodes consisted of a platinum ring or ball, I mm in diame-
ter. 
After application of penicillin powder (Penidural (R), Mycofarm, 
Delft, The Netherlands) into the wound, the skin was closed over the 
myogram wires and around the socket. The animals were warmed artifi-
cially until emerging from anesthesia. 
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Routinely, the EEG was derived bipolarly from the electrodes over 
the left frontal and parietal cortex. No difference in EEG pattern was 
noted, whether the electrode over the frontal cortex was placed either 
anterior or posterior to the coronal suture, or whether the electrodes 
over the right hemisphere were placed either close to the sagittal su-
ture or more laterally (see also Chapter 2). The distance between both 
electrodes from which one signal was derived, influenced the mean am-
plitude of the EEG, but not the pattern. Thus, drug-induced changes in 
amplitude values in these preparations should be compared only to con-
trol circumstances in the same rat. 
Initially, silver screw cortical electrodes were used, manufactur-
ed in the Central Research Workshop of the Medical Faculty, Erasmus 
University Rotterdam. Because this method was time consuming, stain-
less steel screws were purchased and used in subsequent experiments. 
No difference was observed between EEG patterns obtained with both 
types of electrodes. 
The electromyogram (EMG) was derived bipolarly from both neck 
electrodes, and the prefrontal cortical electrode was used as refer-
ence. Initially, insulated copper wire was used to connect the elec-
trodes with the socket. In a few weeks the copper corroded and as a 
consequence the quality of the EMG declined as movement artefacts ap-
peared. Therefore, in later experiments, teflon insulated, twisted 
multistrand stainless steel wires were used. These produced a sustain-
ed, good quality EMG. The connection between the platinum EMG elec-
trode and the wire caused some problems too. Initially, platinum rings 
were used, but they frequently became detached from the wire. A short 
piece of platinum wire with a ball-formed tip could be fixed more effi-
ciently and rendered good EMG's for 2-3 months. 
Rats with chronic electrodes were used for experiments from 8 days 
until about 3 months after implantation. Because the EMG generally de-
teriorated earlier, the rats were only used for about two months for 
experiments in which the EMG was necessary. After 3 months the corti-
cal electrodes sometimes became detached, and therefore the rats were 
not used any longer. 
30 
1 .3.2.2. Semi-chronic electrodes 
Rats with semi-chronic electrodes were used only in lesion experi-
ments (Chapter 8). The electrodes were adapted from a device described 
by De Vas and Bonta (1964) and consisted of one, prefabricated andre-
usable block. Five nail-shaped silver electrodes were connected to an 
8-pin contact socket and then molded into a polymer resin, so that the 
socket protruded upward and the points of the electrodes downward. The 
diameter of the electrodes was 0.7 mm, they protruded 3 mm out of the 
plastic resin and their surface was ribbed. The placing of the elec-
trodes is shown in fig. 1. 3. 
The rats were prepared and placed in the stereotactic apparatus as 
described for the implantation of chronic electrodes. When electrolyt-
ic lesions or sham lesions were made, holes were drilled into the skull 
at a point overlying the target site and needles were lowered into the 
brain. For lesioning, insect pins were used, varnish-isolated except 
for the tip. When a lesion was made, the needle served as anode and 
the ear-bars as cathode. A current of I mA was applicated for 20 s. 
Thereafter the needles were removed. 
Then five holes (diameter 0.5 mm) were drilled in the skull. Aid-
ed by a jig they were placed such that they fitted to the conformation 
of the electrodes in the electrode block. The block was placed on the 
skull with the electrodes over the holes, and using slight pressure, 
the electrodes were pushed into the holes. The block was kept in place 
by the ribbed surface of the electrodes. After the application of pen-
icillin powder, the edges of the incision were closed around the elec-
trode block. 
Rats implanted with this kind of electrode were used for only one 
experimental session, between 6 and 10 days after implantation. After 
about two weeks the electrode blocks loosened spontaneously. Routine-
ly, a left bipolar parieto-occipital derivation was used, with the pre-
frontal electrode as reference. After using these rats, the place and 
extent of the lesions were verified histologically (see Chapter 8). 
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Fig. 1.3. Schematic drawing of the skull (right) and uncov-
ered central nervous system (left) of a rat, showing the plac-
ing of semi-chronic electrodes over the cortex (circles). 
I .3.3. Experimental set-up 
Between the experimental sessions, the rats were caged individual-
ly, and received water and food ad libitum. The daily lighting period 
was from 07.00 h to 21.00 h. On the day before an experiment, the rats 
were weighed and placed in individual cages in a shielded, sound-proof 
cabin to adapt to the environment. They were kept on the same lighting 
schedule as in the previous cages, and received water and food ad libi-
tum. 
On the following day, at about 09.00h, food and water were removed 
from the cages and an 8-pin miniature plug was plugged into the contact 
socket on the rat's head, connecting the electrodes with the EEG appa-
ratus via a flexible cable. The cable was suspended from a swivel and 
was held up by a courttffweight. Thus, the rats could move reasonably 
freely without becoming entangled or gnawing at the cable. However, 
when they were extremely active, as happened sometimes after adminis-
tration of amphetamine or apomorphine (Chapter 5), the cables were 
twisted so many times that the rats had to be disconnected from the 
cables for a short period, in order to turn the cables back. 
The animals were allowed to adapt to being connected to the ca~ 
bles, for at least one hour. Thereafter, the recording of the EEG and, 
in some experiments, the EMG, was started~ Baseline signals were re-
corded for at least one hour before administration of drugs. 
The signals were amplified by Grass model 7P511 amplifiers and 
registered on a Grass model 78 polygraph. Generally, the signals were 
simultaneously registered on a Philips Analog 7 magnetic tape recorder. 
The apparatus contained 6 amplifier channels. Thus, when both EEG and 
EMG had to be registered, as in the sleep experiments, a maximum of 3 
rats could be used simultaneously. In other experiments, 4 rats were 
used in each session: in all rats unilateral EEG was registered, and 
the remaining two channels could be used for either contralateral EEG's 
or EMG's. 
33 
1 .3.4. Route of drug administration 
In practically all experiments the compounds were injected intra-
peritoneally (i.p.). As an alternative route of drug administration, 
intravenous (i.v.) injection into the tail vein was applied in rats 
with semi-chronic electrodes (Chapter 8). Oral administration was re-
jected as being unreliable because of the slower uptake and dependency 
on many variables. 
The arguments for preferring ~.p. over i.v. administration in most 
experiments were as follows: 
a. i.p. administration is easier and can be made more rapidly; 
b. i.p. administration causes less handling stress, because for i.v. 
administration the animals have to be restrained in a narrow cage; 
c. in the literature concerning GHB, this compound was generally in-
jected i.p.; thus, when comparing effects of certain dose-ranges of 
GHB, they should be administered along the same route; 
d. rats bearing chronic electrodes were used for several months; during 
this period the skin over the tail thickened, and in the older rats 
it was very difficult to find the tail vein for i.v. injection. How-
ever, rats with semi-chronic electrodes were used only once, when 
they were young and i.v. injection was relatively easy. Therefore, 
in these rats, drugs were administered i.v. (Chapter 8). 
The following compounds were administered to the rats: 
-Acetazolamide (AAA). Source: Lederle. Dissolved in water. 
Amino-oxyacetic acid-hemihydrochloride (AOAA). Source: K & K Labora-
tories. Dissolved in water, neutralized with I N NaOH. 
-Amphetamine-sulphate. Source : Brocacef. Dissolved in water. 
- Apomorphine-hydrochloride. Source: Sandoz. Dissolved in water with 
added ascorbic acid 0.2 mg/ml, in order to prevent oxidation of the 
compound. 
- (3,4-dihydroxyphenylamino)-2-imidazoline (DPI). Source: Boehringer-
Ingelheim. Dissolved in water, neutralized with O.l N NaOH. 
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-Diphenylhydantoin-sodium (DPH). Source: Brocacef. Dissolved in 
propylene-glycol. 
Sodium-n-dipropylacetate (DPA). Source: Labaz. Dissolved ln water. 
-Ethosuximide (ESI). Source: Chemische Industrie Katwijk. Dissolved 
in water, neutralized with 0.1 N NaOH. 
- Sodium-gamma-hydroxybutyrate (GHB). Source: Egic. Dissolved in wa-
ter. In the experiments described in Chapters 2, 3 and (in part) 4, 
GHB was prepared by heating gamma-butyrolactone (Baker) in the pres-
ence of NaOH and neutralizing with HCl. 
1-Hydroxy-3-amino-pyrrolidone-2 (HA-966). Source: Organon. Dis-
solved in water. 
- Haloperidol. Source: Janssen Pharmaceutica. Dissolved in lactic ac-
id and saline. 
- Mephenytoin (MPH). Source: Brocacef. Dissolved in propylene-glycol. 
-Phenobarbital-sodium (PHB). Source: Brocacef. Dissolved in water, 
neutralized with 0.1 N HCl. 
- Phensuximide (PSI). Source: Chemische Industrie Katwijk. Dissolved 
in propylene-glycol. 
Piribedil. Source: Servier. Dissolved ln 0.1 N HCl, neutralized 
with 0. I N NaOH. 
Trimethadione (TMD). Source: Brocacef. Dissolved in water, neutral-
ized with 0.1 N NaOH. 
The solutions were administered in volumes of 2-5 ml/kg when dis-
solved in water, or 1-2 ml/kg when dissolved in propylene-glycol. In 
control experiments, equal amounts of saline (0.9% NaCl) were adminis-
tered when drugs were dissolved in water, or of propylene-glycol when 
this solvent was used. If necessary, aqueous solutions were diluted in 
saline. 
1.3.6. Frequency analysis 
From characteristic EEG patterns, power and phase spectra were 
computed. An EEG fragment was designated 11 characteristic 11 when it pos-
sessed a recognizable pattern, appearing regularly (either spontaneous-
ly or after administration of a drug), and not being a short transition 
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phase between two other EEG patterns. 
The computations were carried out off line, using a PDP 15 comput-
er. After analog to digital conversion (50 Hz sampling frequency over 
blocks of 1024 points, thus each block covering 20 seconds), the spec-
tra were computed using the Cooley-Tukey Fast Fourier Transform. The 
results were smoothed over 32 points, rendering a frequency resolution 
of (50 : 1024)x(32 : 2)~ 0.8 Hz. In the figures shown, the spectra 
were computed over clusters of J-7 consecutive blocks of 20 seconds 
each. 
1 .3.7. Statistical evaluation 
Values of results are presented as means + standard error of the 
mean (SEM). Where necessary, significance of differences was deter-
mined using two-tailed Student's t-test or paired two-tailed Student's 
t-test. The paired test was used in the experiments described in Chap-
ters 5, 6 and 7; drug-induced effects were ccmpared with control re-
sults in the same session. 
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CHAPTER 2. EFFECTS OF LOW DOSES OF GHB (12.5-100 mg/kg) ON SLEEP 
STAGES IN THE RAT 
2. 1. Introduction 
The state of behavioral sedation, induced by GHB or GEL in several 
animals, has been called "sleep" by many authors (see 1.1. 2.). The 
criterion for this state was, generally, the loss of the animal's 
righting reflex, which, hmvever, points rather to an anesthetic state 
than to natural sleep. EEG phenomena discriminating between SHS and PS 
were not used in these experiments. Moreover, other authors using sim-
ilar doses of GHB and GEL (400 rng/kg and higher) reported induction of 
EEG phenomena similar to the hypersynchronous patterns seen in convul-
sive disorders (see 1.1.4.). Thus, a discrepancy appeared to exist 
between the effects of GHB in these doses and naturally occurring 
sleep, both behaviorally and electrographically. We were interested ln 
investigating whether lower doses of GHB, which do not change the nor-
mally-occurring EEG patterns, might influence the duration of sleep in 
the rat. 
GHB was also reported to induce PS in cats (Jouvet et al., 1961; 
Matsuzaki et al., 1964). However, this effect was not observed by oth-
ers in this species (Drakontides et al., 1962; Winters and Spooner, 
1965 a; Vern and Hubbard, 1971), nor in the chick (Osuide, 1972 b), rat 
(Marcus et al., 1967) or man (Metcalf et al., 1966; Yamada et al., 
1967). In view of these conflicting results, it was tempting to exam-
ine the effect of GHB on PS in the rat. 
2.2. Materials and Methods 
2.2. 1. Experimental design 
Rats with chronically implanted electrodes were used. The report-
ed results were obtained from 9 rats in 11 experimental sessions. 
In preliminary experiments, it was established that the highest 
dose of GHB which does not change normal EEG patterns, is 100 mg/kg. 
Therefore, in these experiments, GHB was administered in doses of 12.5-
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100 mg/kg. Each dose was tested once only in any single rat. Each rat 
was used in 2-4 experimental sessions. Thus, no rat received all doses 
of GHB used. However, each rat received a control treatment (saline) 
at least once. 
In each session, three rats were used. At about 11.30-h, saline 
was administered to one rat, and the two remaining rats each received a 
different dose of GHB. Thereafter, the EEG and EHG were registered 
continuously for at least 4 hours. 
2.2.2. Evaluation of sleep stages 
The states of vigilance of the rats were scored every 30 s for the 
first 4 h after the injection. Scoring was based on the registrations 
of EEG and EMG, according to the criteria of Timo-Iaria et al. (1970). 
These are that a 30 s period with a high EEG amplitude is scored as 
SWS, a low EEG amplitude combined with a high EMG amplitude is referred 
to as "wake" and a low amplitude of both EEG and EMG is designated PS. 
Significance of differences was determined by Student's t-test. 
From characteristic EEG patterns, power spectra were computed (see 
1.3.5.). 
2.3. Results 
2.3. 1. States of vigilance in untreated rats 
Aided by EEG and EMG, a clear discrimination was obtained between 
wake, SWS and PS (fig. 2.1.). The EMG was often contaminated by peaks 
from the electrocardiogram, which, however, did not hamper the evalua-
tion of sleep stages. The ventroflexion, observed elsewhere in rats 
during PS (Khazan et al., 1967) was not always exhibited by our rats, 
possibly because they were hindered by the connecting cables. 
During PS, a clear theta rhythm(6-8 Hz) was seen in the EEG (fig. 
2.1.). A power spectrum of the EEG during the three states of vigi-
lance confirmed the appearance of the theta rhythm especially during PS 
(fig. 2.2.). Derivation of both a lateral and a medial fronto-parietal 
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Fig. 2.1. States of vigilance as distinguished in the rat. 
ECoG - electrocorticogram; EMG = electromyogram. Note that 
the width of the solid band between the peaks in the EMG 
tracings represents the amplitude of the EMG; the peaks are 
contaminations by the electrocardiogram. 
EEG in the same rat (fig. 2.2.b) and their coherence spectrum (fig. 
2.3.) revealed that the theta rhythm during PS appears in a broad area 
in the cortex. 
2.3.2. Effects of GHB on sleep stages 
12.5 and 25 rng/kg GHB had no effect on the EEG nor on the sleep 
pattern of the rats. 50 and 100 mg/kg GHB caused a rise in the dura-
tion of SWS, which persisted for the whole 4 hour period of EEG 
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Fig. 2.2. Power spectra of representative EEG recordings, 
derived from the lateral and medial cortex, during SWS (a), 
PS (b), and wake (c). 
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Fig. 2.3. Coherence spectrum of both recordings from fig. 
2.2.b. The coherence, indicated along the abscissa in 
arbitrary units, is a degree for the correlation between 
two stationary, stochastic processes. The high level of 
coherence at 7-8 Hz indicates the equal appearance of theta 
rhythms during PS, in both medial and lateral cortex. 
registration (fig. 2.4.). The SWS alternated regularly with PS and 
awake periods; during SWS, the rats could be aroused easily by tactile 
or acoustic stimuli. 50 mg/kg GHB caused a slight rise in PS during 
the third hour after injection, but this effect was not seen during the 
rest of the registration period. 
2.4. Discussion 
2.4. 1. Theta rhythm in the cortical EEG 
Visual and automatic analysis of the EEG during PS showed the oc-
currence of a theta rhythm in the cortex. This rhythm, generally reg-
istered in the rat hippocampus during PS (Roldan and Weiss, 1962; 
Timo-Iaria et al., 1970), is believed to be generated there and trans-
mitted to the cortex (Tirno-Iaria et al., 1970). Several authors reg-
istered theta rhythm in the rat cortex during PS (Michel et al., 1961; 
Swisher, 1962; Timo-Iaria et al., 1970). It was noted by Timo-Iaria 
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Fig. 2.4. Percentage of time spent in SWS or PS during the 
4 hours after administration of GHB (mean+ SEM). Significance 
of differences (versus saline controls) waS determined by 
Student's t-test. *p<0.05. 
and co-workers (1970) that this pattern is not observed in all cortical 
registrations, but only ~n derivations from the medial parts of the 
hemispheres. Michel et al. (1961), however, reported the occurrence 
of theta rhythm in the frontal and parietal cortex, 'vhereas Swisher 
(1962) observed theta rhythm in bipolar derivations from the frontal, 
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visual or motor cortex, both unilaterally and bilaterally, as long as 
the electrodes were not placed bilaterally symmetrical. Our results 
show that theta rhythm during PS is obtained from both medial and lat-
eral cortical areas, in contradiction to the restrictions of Timo-Iaria 
et al. (1970), but in agreement with others (Michel et al., 1961; 
Swisher, 1962). 
2.4.2. Effects of GHB on sleep stages 
The results show that GHB, in the dose range of 50-100 mg/kg, may 
increase sleep, as measured electrographically. This GHB effect is 
different, in many respects, from the sedative state induced by higher 
doses of GHB (see 1.1.2.). The latter state is defined by a loss of 
righting reflex, which has nothing to do with natural sleep; the seda-
tion is continuous for 1-2 hours, depending on the dose used, and the 
EEG observed during this state is described as being hypersynchronous 
(see 1.1.4.). On the other hand, during SWS after 50-100 mg/kg, the 
arousability of the animals, the sequence of sleep-wake stages and the 
EEG pattern were similar to those observed during natural sleep. 
The increase in paradoxical sleep induced by 50-IOO mg/kg GHB, as 
observed in the cat (Jouvet et al., 1961; Matsuzaki et al., 1964), was 
not reproduced in the rat. This confirms earlier observations in this 
species (Marcus et al., 1967), in chicks (Osuide, 1972 b) and in man 
(Metcalf et al., 1966; Yamada et al., 1967)~ This discrepancy is not 
likely to be due to a species difference, since, in the cat, conflict-
ing results also exist (Drakontides et al., 1962; Winters and Spooner, 
1965 a; Vern and Hubbard, 1971). Possibly, a difference in interpreta-
tion of EEG states is responsible for the discrepancy. This is proba-
bly the case with the "sws/PS" state, observed by Vern and Hubbard 
(1971) after administration of GHB in cats, which might be scored as 
either SWS or PS. 
The mechanism of action underlying the enhancement of SWS by GHB 
is not at all clear. The serotoninergic neurons in the raphe system 
seem to play a role in the induction of SWS (Jouvet, 1972). It is not 
inconceivable that the reported increase in serotonin synthesis and 
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turnover rate produced by GHB (Spano and Przegalinsky, 1973) plays a 
role in the observed induction of SWS. It is more likely, however, 
that inhibition of the impulse flow in DA neurons by GHB (Roth et al., 
1973) is responsible for the enhancement of SWS. This is because in-
creased activity of DA neurons induce waking, and inhibition of these 
neurons diminish waking, both behaviorally (Lidbrink et al., 1973; 
Jones et al., 1973) and electrographically (Kafi and Gaillard, 1976). 
An attempt has been made to determine whether changes occur in rat 
cerebrospinal fluid GHB levels bet"t;veen the awake and SHS state; how-
ever, no significant differences were observed (Tabakoff and 
Radulovacki, 1976), thus allowing no conclusion to be drawn concerning 
a possible role for naturally occurring GHB in St.JS. 
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CHAPTER 3. INDUCTION OF HYPERSYNCHRONOUS EEG PATTERNS BY 
GHB (200 mg/kg) IN THE RAT 
3. 1. Introduction 
The EEG pattern, observed during the state of behavioral sedation 
induced by GHB, has been reported to possess a very high amplitude and 
was described therefore as "hypersynchronous" or "epileptoid 11 (Winters 
and Spooner, 1965 a,b; 1966; Marcus et al., 1967). In preliminary ex-
periments we found that the lowest dose of GHB, inducing an EEG dif-
fering from normal patterns in the rat, was 200 mg/kg. This was con-
firmed, recently, by Marcus and co-workers (1976). We were interested 
in investigating in detail the effects of 200 mg/kg GHB on EEG pattern 
and behavior in the rat. In particular, we wanted to know whether 
this EEG pattern was different from naturally occurring non-pathologi-
cal patterns, and if so, which pathological state do the GHB-induced 
effects resemble. 
3.2. Materials and methods 
Rats with chronically implanted electrodes were used. GHB (200 
mg/kg i.p.) was administered between 11.30 hand 12.30 h. The power 
spectra, as depicted here, were obtained from three rats; the duration 
of the EEG effects was determined from the mean of eight rats. In 
var~ous series of experiments, not described in this Chapter, another 
60 rats received the same dose of GHB, preceded by control injections 
(saline or propylene-glycol). The effects on EEG and behavior were 
similar, independently of the pretreatment. 
3.3. Results 
3. 3. I. EEG and EMG 
200 mg/kg GHB induced a sequence of EEG patterns, progressing from 
bursts of hypersynchronous waves (300-600 pV, 5-6 c/s) to continuous 
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Fig, 3.1. Effect of GHB (200 mg/kg i.p.) on cortical EEG (C) 
and EMG (M) of a single rat. (a)-(c): baseline EEG patterns. 
(d): the first EEG response to GHB, administered 7 min 
earlier. (e)-(h): subsequent EEG phenomena induced by GHB. 
(i): the first period with continuous desynchronized EEG. 
SWS= slow wave sleep; PPS= preparadoxical sleep. 
hyper synchrony (250-400 -pV, 4-5 c/ s); then, again, hypersynchronous 
bursts were observed and, finally, the normally occurring, alternating 
sleep-wake patterns reappeared. 
The first hypersynchronous bursts appeared 5 min after administra-
tion of GHB and lasted 5-8 s each. During the periods between the 
bursts, a desynchronized EEG appeared. The duration of these interme-
diate periods was about 60 s between the first bursts and diminished 
gradually during the next 10 mln (fig. 3.1. d,e). The neck EMG showed 
a low amplitude during the burst (associated with the immobile posture 
as described below) and a high amplitude during the intermediate peri-
ods. The continuous hypersynchrony which followed the bursts lasted for 
23.38 ~ 5.35 min (n=8). During this period the amplitude of the EMG was 
low. The continuous hypersynchronous EEG consisted of nvo subsequent 
patterns. During the first 10-15 min, the EEG pattern consisted of 
hypersynchronous spikes, followed by one or more slow waves (figs. 3.1.f 
and 3.2.). Thereafter, the amplitude of the spikes gradually decreased 
Fig. 3.2. EEG of a rat, 13 min after administration of GHB, 
showing right (RF-RP) and left (LF-LP) fronto-parietal 
patterns. Arrows indicate some of the spikes, followed by 
slow waves, as mentioned in the text. 
to 200-300 pV (fig. 3.1.g). After the period of continuous hypersyn-
chrony, bursts reappeared with a lower amplitude than before, separated 
by gradually lengthening intermediate periods with a desynchronized EEG 
(fig. 3.l.h). About 20 min later, a desynchronized wake EEG reappeared 
(fig. 3.1 .i), followed by the other, usual, alternating states of vig-
ilance. The total duration of the hypersynchronaus phenomena was 72.13 
~ 3.91 min (n=8). Thereafter, the rats showed a relatively high SWS 
duration, comparable to that induced by 50 or 100 mg/kg GHB. The PS 
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duration however was shorter. 
A bilateral derivation of the EEG (fig. 3.2.) and its phase spec-
trum (fig. 3.3.) show that the spikes obtained during the continuous 
phase of the hypersynchrony were generated synchronously and symmetri-
cally in the contralateral areas of the cortex. 
In fig. 3.4. the power spectra of the EEG of 3 rats showing con-
tinuous hypersynchrony after GHB administration are compared with base-
line SWS periods. During the continuous hypersynchrony, the power 
spectrum showed a higher energy, especially over the frequencies be-
tween 3 and 10 Hz. 
frequency (Hz) 
3 6 10 30 100 
phase 
(degr.) 
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Fig. 3.3. Phase spectrum of the right and left fronto-parietal 
EEG's from fig. 3.2., showing the similarity in phase between 
the two derivations. 
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Fig. 3.4. Power spectra of characteristic EEG patterns induced 
by GHB (200 mg/kg), compared with naturally occurring slow 
wave sleep in 3 rats. 
3.3.2. Behavior 
The rats behaved normally until the appearance of the first hyper-
synchronous EEG burst after GHB administration; i.e. they were active 
and moved around the cage. At the onset of a burst they suddenly stop-
ped moving and remained immobile, with their eyes open, for the dura-
tion of the burst. As soon as the burst stopped, the rats immediately 
resumed their previous motor activity until the next burst appeared. 
This can also be seen from the EMG (fig. 3.1. d,h). When the bursts 
became more frequent, only slight movements of the head were seen 
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during the short intermediate periods. When the hypersynchrony was 
continuous, the animals lay quietly with their eyes half closed. During 
and after the period of the GHB-induced changes in EEG no convulsions 
or other jerky movements 'I:Vere observed .. 
3.4. Discussion 
Three high-amplitude EEG patterns have been described which occur 
naturally in the rat: spindling (fig. 3.1. a), SWS (fig 3.1. b) and 
preparadoxical sleep (PPS), the transitional state between SWS and PS 
(fig. 3.1. c) (Timo-Iaria et al., 1970). PPS, which is not distin-
guished as a separate stage by other authors, is similar to SWS in EEG, 
EMG and behavior, except that the amplitude of the EEG is slightly 
higher, and its high-frequency components are absent. Moreover, the EMG 
amplitude sometimes decreases already during PPS, to its low PS-level. 
Visual and automatic analysis of the EEG hypersynchrony, induced by 200 
mg/kg GHB (fig. 3.1. d-h), showed that it was different frcm the natu-
rally occurring high-amplitude patterns described above: the amplitude 
was higher, the peaks were sharper and they were separated by slow 
waves. This indicates that the behavioral sedation induced by 200 
mg/kg GHB is dissimilar to natural sleep. It confirms the conclusions 
obtained by mere visual observation of the EEG, after the same dose of 
GHB in the rat (Marcus et al., 1976), or higher doses in man, rabbit, 
cat, rat and chick (Schneider et al., !963; Winters and Spooner, 1965 
a,b; Marcus et al., 1967; Osuide, 1972 b) .. These authors considered 
the GHB-induced EEG patterns to be different from those seen during 
sleep or anesthesia. Ir1stead, they called them "epileptoid", because 
of their similarity to EEG patterns observed during human epileptic 
attacks and artificially induced convulsions in animals. 
The synchronous generation of spikes on both sides of the cortex 
points towards a similarity to some type of generalized epilepsy: 
they were generated in a subcortical brain structure, and not in a 
cortical focus. Because convulsions did not occur, this state has been 
compared to "generalized non-convulsive epilepsy" or absence C'petit-
mal") epilepsy (Winters and Spooner, 1965 a; Snead et al., 1976). 
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l'he most striking clinical symptom of absence epilepsy, absence 
episodes, can not be observed in animals. However, a motor parallel of 
absences has been described in the cat during insulin-induced hypogly-
cemla with hypersynchronous EEG phenomena (Waltregny, 1969). Also, the 
short periods of immobility, displayed by our rats during the hyper-
synchronous EEG bursts in the first 10-15 m1n after injection of GHB 
and after the continuous hypersynchrony, might parallel the absence 
episodes of human absence epilepsy. 
Another characteristic of absence epilepsy is the appearance of 
3/s spike-and-wave complexes in the EEG. Such a pattern was induced by 
GHB in the cat (Snead et al., 1976). In the rat, we observed spikes 
alternating with slow waves (figs. 3.1. f and 3.2.), but they appeared 
to be different from the classical spike-and-wave pattern, especially 
in their higher frequency of occurrence (4-5 c/s instead of 3). This 
difference might be due to species properties since spike-and-wave com-
plexes are not produced 1n the rat as readily as in other species 
(McQueen and Woodbury, 1975). 
Thus, in summary, the EEG and behavioral pattern induced by 200 
mg/kg GHB is reminiscent of absence epilepsy with respect to the bilat-
erally symmetrical (generalized) hypersynchronous (epileptoid) EEG and 
the lack of convulsions, which appear to be replaced by an immobile 
posture during the bursts, possibly paralleling absences. 
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CHAPTER 4. EFFECTS OF ANTIEPILEPTIC DRUGS ON GHB-INDUCED 
EEG HYPERSYNCHRONY 
4. I . Introduction 
In view of the reminiscence of GHB-induced EEG hypersynchrony and 
behavior to absence epilepsy, as described in the previous Chapter, it 
was of interest to know whether this hypersynchrony can be antagonized 
by drugs which are effective in the treatment of absence epilepsy. To 
this end we pretreated rats with different types of antiepileptic drugs 
and observed the effects of these compounds on GHB-induced EEG hyper-
synchrony. 
4.2. Materials and methods 
Twelve rats with chronically implanted electrodes were used. The 
time table of the experiments and the arrangement of the injections are 
visualized in fig. 4.1. In each experimental session, 3 or 4 rats were 
used: one received an antiepileptic drug and saline, one was treated 
with the solvent of the antiepileptic drug and GHB (200 mg/kg), and 
both the antiepileptic drug and GHB were administered to the one or two 
remaining rats. The first injection (antiepileptic drug or its 
solvent) was made at about 11.30 h. The period between the first and 
the second injection (GHB or saline) varied for the different antiepi-
leptic drugs, in order to allow the maximal effects of the drug and the 
GHB to coincide (table 4.1.). The antiepileptic drugs were adminis-
tered intraperitoneally, in doses which were effective in antagonizing 
experimental convulsions (table 4.1.). After the second injection, the 
EEG was registered continuously for 2-5 h. 
Each combination of an antiepileptic drug with GHB was adminis-
tered not more than once only to any single rat. The time which 
elapsed between the administration of two consecutive combinations 
of an antiepileptic drug and GHB in any individual rat was at least 
seven days. Each rat received 1-4 times a combination of a different 
antiepileptic agent and GHB. The control treatment of a solvent 
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Fig. 4.1. Time table of the experiments. 
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followed by GHB, was administered 2-5 times to each rat. 
4.3. Results 
The effects of pretreatment with different antiepileptic drugs on 
GHB-induced hypersynchrony are presented in table 4. I. 
Administration of an anticonvulsive dose of TMD followed by a sa-
line injection had no pronounced influence on the EEG or the behavior 
of the rats. After a short period of excitation following the injec-
tion, the rats resumed their usual alternating states of vigilance. 
Sometimes, waves with a relatively high amplitude and low frequency 
appeared for short periods during SWS. The TMD pretreatment blocked 
the appearance of GHB-induced hypersynchrony in all 5 rats tested. 
These rats showed the same EEG pattern as observed after administration 
of TMD and saline. 
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Table 4.1. Effect of antiepileptic drugs on GHB-induced EEG hypersynchrony. 
Drug Dose Time a Clinical Number of experiments 
(mg/kg) (min) indication Total In which GHB· 
(type of hypersynchrony 
epilepsy) was antagonized 
Trimethadione (TMD) 300b 60 absence 5 5 
Sodium-n-dipropylacetate (DPA) 300c 17 absence 4 4 
Ethosuximide (ESI) 300d 60 absence 8 8 
Phensuximide (PSI) 30-300d 60 absenceh 6 0 
Acetazolamide (AAA) 100-300e 60' 110 absenceh 5 0 
Sodium-phenobarbital (PHB) 30f 30' 60 convulsive h 6 2 
Sodium-diphenylhydantoin (DPH) l35b 60 convulsive 6 0 
Mephenytoin (MPH) 70-135g 60' 120 convulsive 4 0 
a)Refers to the time lag between the first injection (antiepileptic drug or solvent) and 
the second one (GHB or saline) in each rat, 
b)(Everett and Richards, 1944) 
d) (Chen et al., 1963) 
f)(Truitt et al., 1960) 
c)(Meunier et al., 1963) 
e)(Chen et al., 1968) 
g)(Chen and Ensor, 1950) 
h)The specificity or efficacy of these compounds is controversial (see 4.4.). 
DPA alone had no influence on the EEG, but caused increased motor 
activity during the first 10 min after administration. Rats treated 
with DPA and GHB showed an EEG similar to that in untreated rats. 
ESI caused a desynchronization of the EEG, lasting for about 110 
m1n. During this period the rats were ataxic. Injections of ESI, 
preceding GHB-treatment, prevented the appearance of the hypersynchrony 
and the EEG remained desynchronized for 50 min after GHB administra-
tion. 
PSI caused a desynchronization of the EEG and a decrease of muscle 
tone, resulting in ataxia. The intensity and duration of both phenome-
na were dose related and lasted for 30-180 min. When doses of 150 or 
300 mg/kg PSI were followed by GHB, the hypersynchronous EEG was not 
seen, but instead, a pattern of polyphasic bursts with intermittent 
electrical silence appeared, starting 10-12 min after the GHB and last-
ing for 50-80 min. This pattern was similar to that observed after 
administration of 500-700 mg/kg GHB alone (Marcus et al., !967; 1976). 
After the polyphasic bursts, a desynchronized EEG appeared 1vhich was 
followed by the alternating states of vigilance. Combination of 30 
or 75 mg/kg PSI with GHB caused intermittent bursts starting 2-3 min 
after GHB administration. These bursts 1vere less frequent and had a 
lower amplitude than those after control GHB injections. Five min af-
ter GHB, continuous hypersynchrony appeared, sometimes interrupted by 
a synchronous EEG for 3-5 s. 50-60 min after GHB the continuous hyper-
synchrony changed into intermittent bursts and 70 min after GHB the EEG 
showed the normal alternating states of vigilance once again. 
AAA had no effect on EEG or behavior. When given in a relatively 
wide dose-range (100-300 mg/kg) and for different periods before GHB, 
it exerted no influence on the GHB-induced hypersynchrony. 
Administration of PHB caused slight sedation 1n the rats, but had 
no influence on the EEG. In combination with GHB it antagonized the 
hypersynchronous EEG pattern in 2 out of 6 experiments, whereas in the 
remaining 4 experiments, GHB caused hypersynchrony, as in control ex-
periments. For the time-limits used, the effect of PHB was independent 
of the duration of the period between the two injections. 
DPH caused ataxia in all rats, but did not change the EEG pattern. 
It had no effect upon the GHB-hypersynchrony. 
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MPH in the highest dose used (135 mg/kg) caused severe ataxia. 
The lower dose (70 mg/kg) caused minor ataxia. Neither dose had any 
influence on the EEG when given alone. GHB, administered after MPH, 
induced polyphasic bursts with intermittent electrical silence, similar 
to the patterns observed after higher doses of GHB (500-700 mg/kg) or, 
as described above, after a combination of PSI and GHB (200 mg/kg). 
4.4. Discussion 
Three of the most specific anti-absence drugs currently used in 
therapy are ESI, DPA and TMD (Aicardi, 1975). These compounds com-
pletely antagonized the appearance of the hypersynchronous EEG pattern 
induced by GHB. DPH and MPH are effective in the treatment of general-
ized convulsive epilepsy (Coatsworth and Penry, 1972), but not against 
absences. Both drugs failed to exert an inhibitory influence on the 
GHB-induced hypersynchrony. In fact MPH seemed to potentiate the ef-
fect of GHB. These results suggest a specific sensitivity of the GEE-
induced EEG pattern to anti-absence drugs. 
The succinimides are generally classified as anti-absence agents 
(Coatsworth and Penry, 1972); however, PSI is less effective, clinical-
ly, against absence epilepsy than the structurally related ESI 
(Aicardi, 1975). In animal experiments, PSI showed a less specific 
anti-absence profile than did ESI and acted more like drugs that are 
effective against psychomotor epilepsy (Chen et al., 1963). This dif-
ference in activity has been attributed to the additional phenyl moiety 
in PSI as compared to ESI (Mercier, 1973). In our experiments, PSI did 
not antagonize and even facilitated the GHB-induced hypersynchrony. 
Conflicting views have been reported concerning the efficacy of AAA in 
controlling absence epilepsy. It has been reported that AAA is the 
most specific anti-absence agent (Millichap and Aymat, 1967), while 
others doubt its clinical effectiveness (Lombroso and Forxythe, 1960). 
In our experiments, AAA in a dose-range of 100-300 mg/kg, which covers 
the anticonvulsive dose (Chen et al., 1968), did not influence the GHB-
56 
induced hypersynchrony. In view of the questionable anti-absence spec-
ificity of PSI and AAA, the results obtained with these compounds are 
not in contradiction to our suggestion that anti-absence drugs specifi-
cally antagonize GHB-induced hypersynchrony. 
PHB showed an ambiguous effect in our experiments; in two cases 
GHB hypersynchrony was antagonized, whereas in the remaining 4 experi-
ments, PHB had no effect on the EEG pattern. This is in agreement with 
our suggestion s~nce PHB, though mainly used against convulsive epilep-
sy, is also reported to be sometimes effective in absence epilepsy 
(Coatsworth and Penry, 1972). 
Of the many animal models used to test potential antiepileptic 
drugs, no single model can give a reliable answer concerning the anti-
absence specificity of the investigated compound (Naquet and Lanoir, 
1973). The most commonly used tests to evaluate possible anti-absence 
efficacy of drugs are seizures, elicited by either intravenous or sub-
cutaneous administration of pentylenetetrazol (Swinyard, 1969). Howev-
er, neither of these methods reproduces absence epilepsy, either behav-
iorally or electrographically, but instead they resemble convulsive ep-
ilepsy. Moreover, activity against pentylenetetrazol is not essential, 
nor constantly predictive, for efficacy in the treatment of absence 
epilepsy (Chen et al., 1963). Recently, two new laboratory models for 
the evaluation of anti-absence drugs have been proposed. One employs 
application of conjugated estrogens to the cerebral cortex of the cat, 
inducing 2-3Hz spike-wave complexes (Fowler and Julien, 1974). The 
other uses photically evoked afterdischarges in the rat (Shearer et 
al., 1976); it is worthwile emphasizing here that photically evoked af-
terdischarges were enhanced by GHB (Kharkevich et al., 1971). Both 
phenomena were antagonized specifically by anti-absence drugs and 
therefore were claimed to be suitable models for testing this type of 
drugs (Fowler and Julien, 1974; Shearer et al., 1976). In view of the 
present results, the GHB-induced EEG may be an additional tool in test-
ing potential anti-absence drugs. 
This GHB effect is not only a possible functional model of absence 
epilepsy (i.e. useful in the evaluation of drugs), but also a phenome-
nological model of this type of epilepsy, imitating some characteristic 
phenomena of absence epilepsy. These phenomena, both electrographical 
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and behavioral, have been mentioned already in the previous chapter, 
and the specific sensitivity to anti-absence drugs may now be added as 
another similarity between the GHB-induced EEG hypersynchrony and ab-
sence epilepsy. 
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CHAPTER 5. THE ROLE OF THE DOPAMINERGIC SYSTEM IN GHB-INDUCED 
EEG HYPERSYNCHRONIZATION 
5. I. Introduction 
In view of the resemblance of GHB-induced EEG hypersynchrony to 
absence epilepsy, as discussed in Chapters 3 and 4, it "tvas of interest 
to investigate the mechanism of action of GHB, at the level of neuro-
transmission, in generating the hypersynchrony. 
The most documented effect of GHB on neurotransmission is the ln-
hibition of the impulse flow in the nigro-neostriatal dopaminergic 
pathway (Walters et al., 1972; Roth et al., 1973; Stock et al., 1973). 
GHB prevents release of DA from these neurons, thus inducing an accumu-
lation of DA in the nerve terminals of the neurons in the corpus stri-
atum (Gessa et al., 1966; Aghajanian and Roth, 1970). A similar accu-
mulation of DA was observed in nerve terminals situated in the nucleus 
accumbens and tuberculum olfactorium (Aghajanian and Roth, 1970). 
In experiments with several animal models of epilepsy, it has been 
suggested that DA receptor stimulation is implicated in antiepileptic 
activity, whereas blockade of DA receptors or a decreased availability 
of DA at the receptor site enhances epileptic phenomena. These models 
include clonic convulsive seizures induced by electroshock in the rat 
(Stull et al., 1973), by auditory stimulation in a sensitive mouse 
strain (Anlezark et al., 1976) and by handling in Mongolian gerbils 
(Cox and Lomax, 1976); hypersynchronous EEG phenomena induced by 
cobalt-implantation in the rat cortex (Dow et al., 1974) and both hy-
persynchronous EEG spikes and myoclonies induced by light flashes 1n 
the photosensitive baboon Papio papio (Meldrum et al., 1975). In addi-
tion, recent data indicate that DA is also involved in cortical EEG de-
synchronization (Kafi and Gaillard, 1976). 
In view of these data, we investigated the possibility that de-
creased stimulation of DA receptors, caused by inhibition of impulse 
flow in dopaminergic neurons, is implicated in GHB-induced EEG hyper-
synchrony. To this end we studied the effects of DA receptor agonists 
and aDA receptor blocker on GHB-induced hypersynchrony. 
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5.2. Materials and methods 
22 rats with chronically implanted electrodes were used. Each rat 
was allowed to recover for at least 7 days bet'tveen t'tvo consecutive ex-
perimental sessions. After adaptation to the environment and baseline 
EEG registration, at 11 .30 h one of the following compounds was admin-
istered: apomorphine-HCl (0.2-8.0 mg/kg), 1-(2-pyrimidyl)-4-piperonyl 
piperazine (piribedil, ET-495; 2.5-10.0 mg/kg), (3,4-dihydroxyphenyl-
amino)-2-imidazoline (DPI; 1-5 mg/kg), d-amphetamine sulphate (1 .5-6.0 
mg/kg), haloperidol (0.5-1 .0 mg/kg) or saline. After a time interval, 
fixed for every drug as specified in table 5~ 1., GHB (200 mg/kg) was 
injected. The chosen time interval between the two injections was such 
that the maximal effects of the drugs would coincide. After the admin-
istration of GHB, the EEG (and in some cases the EMG too) was recorded 
continuously for either 2 hours or until its pattern had returned to 
nonnal, whichever effect occurred later. 
In a series of 4 experimental sessions on any group of 4 rats, 
each of 3 rats initially received a different dose of test canpound, 
the fourth rat receiving an injection of saline. In the succeeding 3 
experiments the doses were randomized so that each rat had eventually 
received all 3 doses of test compound and saline by the end of the 
series. 
In order to investigate the effect of apomorphine, 7 different 
doses were tested, and therefore three groups of rats were used. Thus, 
the rats of each group received three doses plus a saline control 
treatment alternately during 4 successive experimental sessions. In 
the experiments with DPI and haloperidol, one rat in each session re-
ceived only DPI or haloperidol and not GHB. Therefore, only two doses 
of these compounds were tested in combination with GHB. The experi-
ments with DPI were not all carried out on the same rats. 
In preliminary experiments it appeared that some of the drugs did 
not totally antagonize the EEG effects of GHB. Moreover, it was ex-
pected that some drugs might enhance the effect of GHB. Thus, scoring 
the effects of drugs as 11 antagonizing" or 11not antagonizing'' the GHB 
hypersynchrony, as in the experiments mentioned in Chapter 4, was not 
a sensitive enough system for the present experiments. There£ ore, \Ve 
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measured the duration of the GHB-induced hypersynchronous EEG effects, 
from the appearance of the first hypersynchronous burst after GHB ad-
ministration until the disappearance of the last burst. The results 
were evaluated statistically using the paired Student's t-test. 
5.3. Results 
5.3.1. Behavior 
Apomorphine in the dose range of 2-8 mg/kg and all doses of am-
phetamine used, enhanced motor activity in the rats as observed visual-
ly, and induced turning and stereotyped licking and chewing. 1fuen 
apomorphine was followed by GHB the rats lay quiet during periods of 
EEG hypersynchrony. When a combination of amphetamine and GHB was 
followed by EEG hypersynchrony, the rats were less active than after 
injection of amphetamine alone. Following injection of DPI the rats 
showed piloerection and a state of apparent flaccid inactivity, though 
occasionally they walked across the cage for a short period. Also, 
after handling, they were active for about a minute. The other com-
pounds used had no visible effect on the behavior of the rats. 
5.3.2. EEG 
Injection of apomorphine or amphetamine, alone, or followed by a 
saline injection, induced a continuous desynchronized EEG in the rats. 
The duration of this desynchronization was dose dependent: after 0.5 
mg/kg apomorphine it lasted for 30 min, 1 mg/kg of this compound induced 
a desynchronization for 60 min and after the highest dose used (8 mg/kg) 
it lasted for about 90 min. The duration of the desynchronized EEG 
after 0.2 mg/kg apomorphine was not different from that after a saline 
injection. The amphetamine-induced desynchronization lasted from 2 h 
after 1.5 mg/kg up to 3! h after 6 mg/kg. 
The lower dose of DPI (1 mg/kg) induced an apparently normal EEG. 
The higher dose (5 mg/kg) induced a mainly desynchronized EEG for 2-3 
h with occasional groups of hypersynchronous bursts. Such a group 
61 
consisted of 4-8 bursts and lasted for 1-2 min. Between the groups a 
continuous desynchronized EEG was seen for 3-5 min. Each burst consis-
ted of 5-10 peaks (300-400 ~V) and lasted for 2-3 s. When compared to 
the GHB-induced bursts, those after DPI were somewhat lower and occur-
red less frequently, while the peaks were closer to each other. 
The EEG of piribedil- or haloperidol-injected rats was not differ-
ent from that after a saline injection. Haloperidol, in the dose range 
used, had no visible synchronizing effect on the EEG. 
Pretreatment of rats with apomorphine, piribedil or haloperidol 
had no effect on the pattern of the GHB-induced EEG hypersynchrony, nor 
on its duration (table 5.1 .). Amphetamine (I .5-6.0 mg/kg), however, 
antagonized the GHB-induced hypersynchrony in most rats (table 5.1 .). 
In this case a continuously desynchronized EEG was seen and lasted for 
about 3 h. The lower dose of DPI (1 mg/kg) had no influence on the 
effect of GHB; the higher dose (5 mg/kg) however, significantly pro-
longed the duration of the GHB-induced hypersynchrony (table 5.1 .). 
5.4. Discussion 
Apomorphine and piribedil are both direct DA receptor stimulants 
(Ernst, 1967; And§n et al., 1967; Corradi et al., 1971). Both com-
pounds block GHB-induced accumulation of DA in rat whole brain 
(Handforth and Sourkes, 1975), rat neostriatum (Walters and Roth, 1974) 
and rat cingulate and frontal cortex (Pericic and Walters, 1976). This 
effect was suggested to be due to stimulation of presynaptic DA recep-
tors (Walters and Roth, 1974). In the dose ranges used here, apomor-
phine and piribedil may have stimulated both pre- and postsynaptic DA 
receptors (StrOmbom, 1976; Corradi et al., 1972). Horeover, the pre-
sent dose range of apomorphine covers the doses which are effective 
against experimental seizures (Stull et al., 1973; Dow et al., 1974; 
Meldrum et al., 1975; Anlezark et al., 1976; Cox and Lomax, 1976). The 
dose range of piribedil, antagonizing epileptic phenomena induced by 
photic stimulation in the baboon, Papio papio, (Meldrum et al., 1975) 
was covered by the doses we used. The failure of apomorphine and piri-
bedil, and of the DA receptor blocker haloperidol, to modulate the GHB-
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Table 5.1. Duration of GHB-induced EEG hypersynchrony after 
pretreatment with different drugs. 
Pretreatment Timea 
Control 
Apomorphine 
Control 
Piribedil 
Control 
DPI 
Control 
Amphetamine 
Control 
Haloperidol 
(min) 
0 
20 
20 
10 
30 
Dose 
(mg/kg) 
0.2 
0.5 
0.7 
1.0 
2.0 
4.0 
8.0 
2.5 
5.0 
10.0 
1.0 
5.0 
1.5 
3.0 
6.0 
0.5 
1.0 
Duration b 
(min) 
62.8 ± 5.6 
39.8 ± 13.3 
60 .3 ± 7 .3 
55.3 ± 5.2 
66.0 ± 15.1 
71.4 ± 9.6 
65.0 ± 4.1 
73.0 ± 9.1 
66.0 ± 5.3 
76.3 ± 9.1 
72.8 ± 6.5 
75.8 ± 2.7 
72.8 ± 2.5 
78.0 ± 12.7 
136.8 ± 9. 2* 
74.5 ± 5.0 
4.5 ± 2.6* 
18.5 ± 18.5* 
9.8 ± 9.8* 
70.0 ± 4.3 
88.3 ± 12.8 
77.3 ± 10.9 
(12) 
(4) 
(4) 
(4) 
(4) 
(8) 
( 4) 
(4) 
(4) 
( 4) 
(4) 
( 4) 
(4) 
(4) 
(4) 
(4) 
(4) 
(4) 
(4) 
(4) 
(4) 
(4) 
a)Time refers to the interval between the pretreatment with 
the drug in question, and GHB-administration, 
b)Values are means + SEM. Numbers of observations are given 
in brackets. Significance of differences (versus saline 
controls) was determined by paired, two-tailed Student'~ 
t-test. *: p<O.OS, 
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induced EEG hypersynchrony in the present experiments, indicates that 
inhibition of the nigrostriatal dopaminergic system is not likely to be 
responsible for the GHB hypersynchrony. This is in accordance with the 
observations that striatectomy has no intluence on the EEG or behav-
ioral effects of GHB in the cat (Marcus et al., 1976) and that, in the 
rat, after striatectomy, pentylenetetrazol-induced EEG seizures remaln 
unaltered, while the threshold for convulsions is elevated (Avakyan, 
1976), indicating that the neostriatum is not involved in EEG hypersyn-
chrony. 
Amphetamine 1s specifically effective in the treatment of absence 
epilepsy (Livingston et al., 1948). Its inhibitory action on the GHB-
induced EEG hypersynchrony, in the present study, is in accordance with 
the effect of other specific anti-absence drugs (see Chapter 4). This 
supports the hypothesis that some similarity exists between the effects 
of 200 mg/kg GHB in the rat and absence epilepsy in man, and that this 
phenomenon might be a suitable tool for testing potential anti-absence 
drugs. 
Amphetamine increases the availability of central catecholamines 
for their receptor sites by enhancing their release and inhibiting 
their reuptake and biotransfonnation. Thus, amphetamine may, indirect-
ly stimulate central catecholamine receptors. Anticonvulsive actions 
of amphetamine in two animal models of epilepsy, namely electroshock 
and pentylenetetrazol convulsions, appeared to be mediated through in-
direct stimulation of noradrenaline receptors (Rudzik and Johnson, 
1970; Riffee and Gerald, 1976). However, the present results do not 
permit definitive conclusions to be drawn concerning the mode of action 
of amphetamine in antagonizing the GHB-induced hypersynchrony. Never-
theless, indirect stimulation of noradrenergic receptors might be re-
sponsible for this antagonistic effect. 
DPI has become of interest only recently, and its pharmacological 
properties have not yet been studied extensively. In the snail Helix 
aspersa, DPI has been found to be a selective agonist at DA receptors 
mediating neuronal inhibition (DA. receptors); these receptors are 
1 
pharmacologically distinct from excitation-mediating DA receptors (DA 
e 
receptors), which are stimulated by apomorphine (Struyker Boudier et 
al., 1975). Two anatomically different DA systems are proposed for 
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many animals, including the rat (Fuxe et al., 1975; Cools and Van 
Rossum, 1976; Cools et al., 1976). As far as the rat is concerned, DA 
e 
receptors predominate in the neostriatum, whereas DA. receptors, the 
l 
type activated by DPI, might occur mainly in the limbic system (Cools 
and VanRossum, 1976; Cools et al., 1976). It is worthwhile emphasiz-
ing that a sufficiently high dose of DPI (5 mg/kg) prolonged the dura-
tion of the G HE-induced hypersynchrony. This might indicate that in-
hibition of the mesolimbic DA system by stimulation of DA. receptors 
l 
has a facilitatory effect on the generation of GHB-induced EEG hyper-
synchrony, possibly by inhibition of a seizure-suppressing mechanism. 
On the other hand, also GBL, the precursor of GHB, was suggested to 
exert an inhibitory effect on the mesolimbic DA system ~uxe et al., 
1975) and may, thus, inhibit this seizure-suppressing mechanism. This 
might explain not only the excitatory effect of GHB, but also the syn-
ergism between GHB and DPI. This line of thought makes it also under-
standable that apomorphine did not antagonize GHB hypersynchrony, since 
both compounds would act on different DA-systems. 
Another property of DPI is its ability to form a complex with 
pyridoxal phosphate (Th. De Boer, personal communication). Pyridoxal 
phosphate is a cofactor for many enzymes, including glutamic acid de-
carboxylase (GAD), the enzyme catalyzing the synthesis of GABA from 
glutamate (see fig. 6.1 .). Thus, it is conceivable that DPI inhibits 
GAD activity, as do many other pyridoxal phosphate complexing agents 
(Tapia, 1974). GAD inhibition is an important factor in the generation 
of various epileptic phenomena (Wood and Peesker, 1974). Thus, it is 
conceivable that the enhancement, by DPI, of the present epileptic 
phenomenon, namely the absence-like effect of GHB, is originated by 
inhibition of GAD. Moreover, GHB itself is also a potent GAD inhibitor 
(Godin and Mark, 1967; Clifford et al., 1973; Dye and Taberner, 1975; 
Tunnicliff, 1976), and this property is probably involved in the gener-
ation of GHB hypersynchrony (see Chapter 6). 
Evidently, a more specific experimental approach is necessary to 
elucidate the role of DPI in GHB-induced EEG hypersynchrony. The pos-
sibility cannot be excluded that different types of DA receptors might 
have different roles in epileptic phenomena, but in view of the results 
and conclusions of the next Chapter, it appears probable that the 
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enhancement of GHB-hypersynchrony by DPI can be explained by an inhibi-
tion of GABA synthesis. 
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CHAPTER 6. THE ROLE OF GABA METABOLISM IN GHB-INDUCED 
EEG HYPERSYNCHRONIZATION 
6.1. Introduction 
Evidence has been collated from many investigations, indicating 
that modulation of the availability of gamma-aminobutyric acid (GABA) 
for its receptor sites~ either by inhibition of its metabolism or by 
blockade of its receptors, is directly related to epileptic phenomena 
(Meldrum, 1975). The activity of the GABA synthesizing enzyme glutamic 
acid decarboxylase (GAD) (fig. 6.1 .) appeared to be the most important 
DPI? 
GHB AOAA DPA 
-t/-l -l 
GAD GABA-T SSA-DH 
GLU GABA SSA SA 
Fig. 6.1. Schematic outline of a part of the GABA-shunt of 
the citric acid cycle, showing synthesis and metabolism of 
GABA, the enzymes involved and some drugs inhibiting the en-
zymes. Abbreviations used: metabolites: GLU =glutamic acid; 
GABA = gamma-arninobutyric acid; SSA succinate semialdehyde; 
SA= succinic acid; enzymes: GAD =glutamic acid decarboxylase; 
GABA-T=GABA-transaminase; SSA-DH = SSA-dehydrogenase; drugs: 
DPI = (3,4-dihydroxyphenylamino)-2-imidazoline; GHB =gamma-
hydroxybu.tyric acid; AOM = amino-oxyacetic acid; DPA = n-
dipropylacetate. 
factor in the antiepileptic action of the GABA-system, the continuous 
release of GABA being dependent on its synthesis (Tapia, 1974). More-
over, a good correlation exists between GAD inhibition and induction of 
convulsions by some drugs (Wood and Peesker, 1972; 1973; Tapia., 1974). 
Wood and Peesker (1974) developed an equation on an empirical basis 
providing a relationship between the excitable state of the brain and 2 
function of GABA metabolism. The concept embodied in the equation is 
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that the excitable state of the brain is determined primarily by the 
rate of synthesis of GABA by GAD, but that the concentration of GABA ln 
the cells also plays a role (Wood and Peesker, 1974). 
GHB is an inhibitor of GAD activity in vivo in the brains of mice 
(Clifford et al., 1973) and rats (Godin and Mark, 1967; Tunnicliff, 
!976), and in mouse brain tissue in vitro, GHB inhibited GAD competiti-
vely (Dye and Taberner, 1975). Thus, it is conceivable that the GHB-
induced EEG hypersynchrony, reminiscent of absence epilepsy, is related 
to modulation of GABA metabolism. 
In order to collect additional evidence for a relationship between 
GHB effects and the GABA system, we prevented GABA biotransformation by 
inhibiting the transaminating enzyme GABA-T (fig. 6.1.) with amino-
oxyacetic acid (AOAA) (Wallach, 1961; Baxter and Roberts, 1961), a sub-
stance with anticonvulsive properties in several animal models of epi-
lepsy (DaVanzo et al., 1961; Wood and Peesker, 1973). The effect of 
AOAA on the duration of GHB-induced EEG hypersynchrony was then mea--
sured. 
6.2. Materials and methods 
8 rats with chronically implanted electrodes were used, divided 
into two groups of 4 rats each. Between two consecutive experimental 
sessions, the rats were allowed to recover for at least seven days. 
In the first experiment of a series of 4, on each group, one rat re-
ceived a saline injection and the 3 other rats were treated with AOAA-
hemihydrochloride in doses of 7.5, 15 or 30 mg/kg intraperitoneally 
(i.p.). In the succeeding three experimental sessions, these pretreat-
ments were randomized, so that eventually, the rats of each group re-
ceived each pretreatment alternately. After a fixed period, I h 15 
min in one group and 5 h 30 min in the other, the rats received GHB 
(200 mg/kg i.p.). In the group where the interval between both in-
jections was 5 h 30 min, the rats received the first injection immedi-
ately at the onset of the session, without an initial adaptation period 
or baseline EEG registration. In both groups, after the GHB injection, 
the EEG was registered continuously for 2-3 h. 
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As in the previous chapter, the total duration of the EEG hyper-
synchrony after GHB administration was measured. Additionally, the 
duration of continuous hypersynchrony was also determined. Continuous 
hypersynchrony was defined as a period of at least one minute of un-
interrupted EEG hypersynchrony. The total duration of such periods 
was then calculated. Thus, "continuous hypersynchrony" does not mean 
that during the whole period the EEG was uninterrupted by patterns of 
lmver amplitude; in many cases several scattered periods of continuous 
hypersynchrony were observed within the total duration of hypersyn-
chrony. 
6.3. Results 
AOAA in doses of 7.5 or 15 mg/kg, when injected alone, had no ef-
fect on the EEG nor on the behavior of the rats. 30 mg/kg induced a 
synchronous slow wave EEG; the rats behaved sluggishly. 
The lowest dose of AOAA (7.5 mg/kg) had no effect on the duration 
of the GHB-induced hypersynchrony but the highest dose (30 mg/kg) pro-
longed the duration significantly in both series of experiments (fig. 
6.2. A,B). The effect of 15 mg/kg AOAA was dependent on the duration 
of the pretreatment period: when injected 1 h 15 min prior to GHB, it 
tended to prolong the duration of the hypersynchrony (fig. 6.2. A), 
but when injected 5 h 30 min before GHB this dose significantly inhi-
bited the duration of the hypersynchrony (fig. 6.2. B). 
The continuous hypersynchrony followed the changes observed for 
the total duration of hypersynchrony, but never reached significant 
differences versus control treatments. 
6.4. Discussion 
The mechanism of action of AOAA possesses a dual character in two 
respects; the results, obtained with this compound, wil~ be interpreted 
accordingly. 
First, the antiepileptic action of AOAA involves two mechanisms, 
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Fig. 6.2. Effect of AOAA, injected I h 15 min (A) or 5 h 30 
min (B) prior to GHB (200 mg/kg), on the duration of GHB-
induced EEG hypersynchrony. White bars: total duration of 
hypersynchrony; hatched bars: duration of the continuous phase 
of hypersynchrony. Values are means + SEM from 4 rats. 
Significance of differences (versus saline-injected controls) 
was determined by paired, two-tailed Student's t-test. *p<O.OS. 
as described by Wood and Peesker (1976). One involves GABA metabolism 
and is maximally effective 6 h after AOAA administration. It is the 
sole mechanism counteracting convulsions induced by allylglycine. 
These convulsions are closely related to GAD inhibition by allylglycine 
(Fisher and Davies, 1976) and their antagonism by AOAA would seem to be 
mediated by elevation of GABA levels (Wood and Peesker, 1976). 1he 
other mechanism, not involving GABA metabolism, is maximally effective 
1.5 h after AOA.A injection and is absent after 6 h. It is the sole 
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factor in the action of AOAA operative against electroshock convulsions 
but its basic mechanism is unknown (Wood and Peesker, 1976). The pre-
sent results show that the middle dose of AOAA (15 mg/kg) antagonized 
the GHB hypersynchrony if injected 6 h before the appearance of the 
maximal GHB effect. The same dose, however, administered 1 h 45 min 
before the maximal effect of GHB, did not reduce the duration of the 
GHB hypersynchrony, but rather tended to prolong it as it did the dura-
tion of GHB-induced loss of righting reflex (Benton et al., 1973). 
Interpreting these results in terms of the above theory, a temporal 
relationship emerges between the antagonism of GHB hypersynchrony by 
AOAA and the maximal involvement of GABA metabolism in the antiepilep-
tic activity of AOAA. On the other hand, at the moment when the GABA-
related antiepileptic mechanism of AOAA is submaximal, but the non-GABA 
mechanism is maximal, no inhibition of GHB hypersynchrony was observed. 
These results do not provide direct evidence indicating that the GHB-
induced EEG hypersynchrony is mediated via the GABA system. They do 
indicate, however, that the GHB effects are very much influenced by 
changes in GABA metabolism. 
The second dual mechanism of AOAA might explain why its antiepi-
leptic action, 6 h after administration, is only exerted by the middle 
dose. AOAA, being an anticonvulsant in low doses (5-25 mg/kg in mam-
mals,~ 5 mg/kg 1n chick), also shows convulsant actions at higher 
doses (DaVanzo et al., 1961; Meldrum et al., 1970; Osuide, 1972 a; 
Wood and Peesker, 1973). This has been explained on the basis of its 
specific inhibition of GABA-T at lower doses, thus enhancing brain GABA 
concentration, while at higher doses (over 25 mg/kg), AOAA also inhi-
bits GAD (fig. 6.1 .) (Wood and Peesker, 1973), counteracting GABA for-
mation and sensitizing the animal to epileptogenic stimuli (Meldrum, 
1975). The latter mechanism might act synergistically with the GAD-
inhibiting action of GHB. Thus, the prolongation of GHB hypersynchrony 
6 h after pretreatment with 30 mg/kg AOAA may be due to synergistic 
GAD-inhibition by both compounds, whereas 15 mg/kg, a dose which par-
ticularly inhibits GABA-T, while having less influence on GAD, antago-
nized GHB. The effect of the lowest dose of AOAA, 7.5 mg/kg, on GABA 
metabolism is probably too small to influence GHB hypersynchrony. 
The specific anti-absence drug n-dipropylacetate (DPA) is a 
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blocker of the enzyme succinic acid semialdehyde dehydrogenase (Harvey 
et al., 1975; Anlezark et al., 1976), which is responsible for the sec-
ond, rate-limiting step in GABA breakdown (fig. 6.1.). Our previous 
finding that DPA antagonizes the GHB-induced EEG hypersynchrony (see 
Chapter 4) might thus support our suggestion that GABA-metabolism is 
involved in GHB-hypersynchrony. The stronger inhibition of GHB hyper-
synchrony by DPA as compared to AOAA might be due to the fact that DPA 
blocks the rate-limiting step in GABA breakdown. The analogous finding 
that ethosuximide inhibits GABA-T activity (Sawaya et al., 1975) might 
explain the inhibition of GHB hypersynchrony by this specific anti-
absence agent as reported in Chapter 4. Conversely, the enhancement of 
GHB-induced hypersynchrony by DPI (see Chapter 5.3.) might be attribut-
ed to its possible counteraction of GABA synthesis by GAD inhibition 
(fig 6.1 .) through forming a complex with pyridoxal phosphate (see 
Chapter 5. 4.). 
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CHAPTER 7. THE EFFECT OF HA-966 ON GHB-INDUCED EEG 
HYPERSYNCHRONIZATION 
7. 1. Introduction 
The synthetic compound 1-hydroxy-3-amino-pyrrolidone-2 (HA-966) 
resembles GHB and GEL in many respects. Its chemical structure, pos-
sessing a 4-carbon chain, is related to the butyrate derivatives GABA, 
GHB and GEL (fig. 7.1 .), though it might also fit the receptors of 
CH -CH-NH I 2 I 2 
CH2 C=O ~N/oH 
HA-966 
GEL 
CH -CH -CH -COOH I 2 2 2 
NH 2 
GABA 
CH -CH -CH -COOH I 2 2 2 
OH 
GHB 
Fig. 7.1. Structural relationship between HA-966 and the 
butyrate derivatives GABA, GHB and GEL. 
putative amino acid neurotransmitters (Davies and Watkins, 1973). Ad-
ministration of HA-966 to rats, rabbits and monkeys induced a sedative 
state and EEG hypersynchrony, similar to those caused by GHB and GEL 
(Bonta et al., 1971). HA-966 was shown to inhibit the impulse flow in 
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the nigro-neostriatal DA system (VanValkenburg, 1976; Walters and 
Roth, 1976), antagonizing DA release from striatal nerve endings and 
thus inducing, like GHB and GBL, an increased DA concentration in the 
corpus striatum (Bonta et al., 1971; Hillen and Noach, 1971; Hillen, 
1972). Another resemblance to GHB is the reported inhibition of GAD by 
HA-966 (Hillen et al., 1969) and a probably related decrease in brain 
GABA concentration (MOhler et al., 1975). 
In view of these similarities, it was of interest to investigate 
the effect of HA-966 on GHB-induced EEG hypersynchrony. 
7.2. Materials and methods 
Four rats with chronically implanted electrodes were used in a 
series of 4 experimental sessions. In each session, after I h for a-
daptation to the connecting cables and 1 h baseline EEG registration, 
the 4 rats were pretreated with saline or 2.5, 5 or 10 mg/kg HA-966 
respectively. 15 min later GHB (200 mg/kg) was administered to all the 
rats. The EEG was then registered continuously for 2-3 h. In the 4 
successive sessions, the pretreatments "tolere randomized, so that, even-
tually, each rat received each pretreatment once. Between the ses-
sions, the rats were allowed to recover for at least 7 days. 
As in the previous chapter, the total duration of EEG hypersyn-
chrony and the duration of the continuous hypersynchrony were deter-
mined separately. The pattern of polyphasic EEG spikes with intermit-
tent electrical silence was counted as continuous hypersynchrony. 
7.3. Results 
Pretreatment with HA-966 caused a dose-related increase in the 
duration of both total and continuous GHB-induced EEG hypersynchrony 
(fig. 7.2.). The values obtained after each dose of HA-966 were not 
only different from control values, but also from the effects of other 
doses. Exceptions to this "tvere the duration of continuous hypersyn-
chrony after 2.5 mg/kg HA-966, which was not different from the control 
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Fig. 7.2. Effect of HA-966, injected 15 min prior to GHB 
(200 mg/kg), on duration of GHB-induced KEG hyper synchrony. 
White bars: total duration of hypersynchrony; hatched bars: 
duration of the continuous phase of hypersynchrony. Values 
are means + SEM from 4 rats. Significance of differences 
(versus saline-injected contro~s) was determined by paired 
two-tailed Student's t-test. p<O.OS. 
value, and the total durations of hypersynchrony after pretreatment 
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with 2.5 and 5 mg/kg, which were also not significantly different. 
The highest dose of HA-966 used, 10 rng/kg, in combination with 200 
mg/kg GHB, induced an EEG pattern consisting of polyphasic spikes sepa-
rated by short isoelectric periods, as observed after sole administra-
tion of 500-700 mg/kg GHB in the rat (Marcus et al., 1967; 1976). 
The behavior of the rats, pretreated with HA-966, was similar to 
that of animals which had received only 200 mg/kg GHB, on the under-
standing that the duration of the behavioral sedation was prolonged to 
the same measure as was the EEG hypersynchrony. 
7.4. Discussion 
The results clearly show the synergistic action of HA-966 and GHB. 
This might indicate a similar mechanism of action of these compounds. 
As stated in the introduction, HA-966 and GHB have in common both an 
antagonistic action on the nigra-striatal DA neurons and an inhibition 
of GABA synthesis. The present results, however, do not distinguish 
between either one or the other of these possibilities being involved 
ln the hypersynchronizing effect of HA-966. 
GHB has been reported to increase brain levels of the putative 
excitatory amino-acid neurotransmitters glutamate (Promislov and 
Solovjova, 1973) and aspartate (Margolis, 1969). As far as the latter 
compound is concerned, the increase seems to be caused by inhibition of 
its metabolism (Margolis, 1969). Therefore, a relationship has been 
suggested between the excitatory effect of GHB on the EEG and the en-
hancement of glutamate and aspartate levels by GHB (Marcus et al., 
1976). One would then expect that GHB acts through enhancement of the 
excitatory action of glutamate and aspartate. HA-966, however, is a 
selective antagonist of neuronal excitation induced by glutamate and 
aspartate (Davies and Watkins, 1972; Curtis et al., 1973). The present 
results show that HA-966 and GHB act synergistically. Therefore, it 
seems unlikely that GHB induces EEG hypersynchrony by increasing gluta-
mate or aspartate in brain. 
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CHAPTER 8. THE ROLE OF THE NIGROSTRIATAL SYSTEM IN SEDATION AND 
EEG SYNCHRONY, INDUCED BY HA-966 
8.1. Introduction 
The involvement of DA neurotransmission 1n EEG desynchronization 
and antiepileptic mechanisms has been emphasized in Chapter 5. Both 
GHB and HA-966 inhibit DA neurotransmission, at least in the nigra-
striatal system, a bundle of DA neurons with their cell bodies in the 
substantia nigra compacta (SNC) and terminating in the corpus striatum. 
Therefore, it was conceivable that this inhibitory effect of GHB and 
HA-966 might be involved in the generation of EEG phenomena by these 
compounds. It appeared, however, that modulation of DA-neurotrans-
mission did not influence the GHB-induced EEG hypersynchrony, suggest-
ing that involvement of the DA system in this epileptoid feature is un-
likely (Chapter 5). In order to investigate whether the synchronizing 
and sedating effects of HA-966, similar to those observei after GHB 
(Bonta et al., 1971), are mediated through its influence on the nlgro-
striatal DA system, we compared the effects of HA-966 in rats with 
bilaterally lesioned or intact SNC. 
8.2. Materials and methods 
Rats with semi-chronically implanted electrodes were used (see 
1.3.1.2.). Lesions were made in the SNC, according to the atlas of 
KOnig and Klippel (1963), using the following parameters: A (frontal 
plane) 2.4 mm; L (sagittal plane) 1.8 mm and H (horizontal plane) 2.1 
mm. Immediately after lesioning, the cortical electrodes were implant-
ed. Histological analysis of the lesions was performed and only the 
results from rats with a totally destroyed SNC were considered. In 
these rats some damage to the structures adjacent to the SNC was noted. 
The results described here were obtained from 4 intact and 8 SNC-
lesioned rats. 
Each rat was used once only for an experiment, 7-10 days after 
implantation. In each session, 1 intact and 4 lesioned rats were used. 
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Before the experiments, the rats were kept overnight in the sound-proof 
cabin. At 09.00 h, water and food were removed from the cages and the 
rats were connected with the cables to the EEG apparatus. At about 
11.00 h, baseline registrations were started. 
The EEG registrations were made as follows. Every 30 min the EEG 
was registered for 60 s. Arousal was then induced by acoustic stimula-
tion, using a sound generator (200 Hz, 20 dB for 2 s). Thereafter, the 
EEG was registered for another 90 s. The amplitude of the registered 
EEG was averaged (by a Grass 7P3) and then integrated (by a Grass 
7P10). The integrator was calibrated so that 20 resets in a I min 
period corresponded to 150 pV. The number of integrator resets was 
determined as a whole for the 60 s pre-stimulation period and separate-
ly for every 10 s interval of the post-stimulation period. The average 
voltage of each interval was then calculated. 
Between 11.00 hand 13.00 h, 4 such pre- and post-stimulation 
EEG's were registered. The mean of the last 3 registrations only was 
used, in order to exclude variations due to adaptation. At about 13.00 
h, HA-966 (10 mg/kg intravenously) was administered to all rats. At 
30, 60 and 90 min after injection, acoustic stimulation was applied and 
the amplitude values of the EEG's registered during each of the pre-
and post-stimulation intervals were calculated. The amplitude value of 
each interval was averaged over the three post-injection registrations. 
Thus, each rat served as its own control before and after drug adminis-
tration. Finally, mean and SEM of the amplitude values were calculated 
for each interval and for each group of rats (lesioned or intact) 
before and after HA-966 injection. 
After the experiment, the rats were killed and the brains of le-
sioned rats were immersed in a neutralized, 10% formalin solution for 
fixation. After at least a week the brains were embedded in 12% gela-
tin and again fixed in formalin for at least 2 days. After being im-
mersed in 20% alcohol for 24 h, the brains were mounted on the freezing 
stage of a microtome. Serial transversal sections (30 pm in thickness) 
were collected from the region of the SNC and stained by Cresyl-violet. 
The site and extent of the lesion was then established. As mentioned 
before, only results from rats with totally destroyed SNC were used. 
A schematic drawing of a representative SNC lesion is shown in fig. 8.1. 
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Fig. 8.1. Schematic drawing of a transversal section 
of a rat brain (A = 2180 p according to the atlas of 
KOnig and Klippel, 1963) showing the extent of the lesion 
in the Substantia nigra compacta in a representative rat. 
Black: totally destroyed; grey: proliferation of glia 
cells. Abbreviations used: 
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8.3. Results 
Administration of HA-966 (10 mg/kg) induced inactive behavior, 
which lasted for about two hours. 
The results, depicted in fig. 8.2., show that, before administra-
tion of HA-966, the acoustic stimulation caused a decrease in amplitude 
ampl. value 
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Fig. 8.2. Effect of HA-966 (10 mg/kg i.v.) on EEG amplitude 
before and after acoustic stimulation in rats with lesioned 
and intact SNC. Each point represents the mean + SEM of 4 
(intact) or 8 (lesioned) rats. 
value, pointing towards an EEG desynchronization characteristic for 
arousal and lasting for 40-50 s. When HA-966 was injected, the ampli-
tude value before stimulation was higher than in the absence of HA-966, 
thus indicating an EEG synchronizing effect of HA-966. The arousal 
induced by acoustic stimulation was prevented by HA-966, emphasizing 
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the sedating effect of this compound. 
No significant differences were observed between normal and SNC-
lesioned rats, either in the effect of an acoustic stimulus, or in the 
influence of HA-966. 
8.4. Discussion 
The present results confirm the synchr0nizing effect of HA-966 on 
the cortical EEG of the rat as observed by Bonta and co-workers (1971) 
and demonstrate its inhibitory influence on the EEG arousal response. 
It was shown, however, that these effects of HA-966 do not depend 
on the integrity of the nigra-striatal DA system. This might indicate 
that the inhibitory effect of HA-966 on nigrostriatal neurotransmission 
is not involved ln the generation of EEG synchronization. This paral-
lels the effect of GHB, as suggested in Chapter 5, in that the EEG 
effects of neither of these compounds are influenced by modulation of 
DA receptor stimulation. This parallel might form another similarity 
between GHB and HA-966. 
The question might be raised as to whether an electrolytic lesion 
is selective enough in this kind of experiment, because it always de-
stroys brain structures adjacent to the target structure. Thus the 
theoretical possibility exists that deactivation of an adjacent struc-
ture compensates for the effect of the lesion in the target structure. 
In the last decade, the compound 6-hydroxy-dopamine (6-0HDA) has been 
used to produce specific lesions of catecholamine-containing nerve 
cells (Kostrzewa and Jacobowitz, 1974). It is, however, difficult to 
induce 6-0HDA lesions in DA neurons only, sparing noradrenalin-con-
taining cells. Moreover, when injected locally to destroy a specific 
structure, 6-0HDA may leak to other parts of the brain and thus damage 
catecholamine cells elsewhere. 
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CHAPTER 9. GENERAL DISCUSSION AND CONCLUSIONS 
9.1, EEG and behavioral effects of GHB: resemblance to 
absence epilepsy 
Several results obtained in the present series of investigations 
point to-h'ards a similarity between the phenomena induced by GHB and 
those characteristic of absence epilepsy. 
The EEG pattern, induced by GHB in cats and rats, has been called 
"epileptoid" because of its high amplitude (hypersynchrony) and the 
occurrence of spikes (Winters and Spooner, 1965 a,b; Marcus et al., 
1967). This was confirmed in the present experiments, using a power 
spectrum of the EEG. The simultaneous appearance of the hypersynchro-
nous phenomena in both cortical hemispheres, observed both visually and 
in a phase spectrum of the EEG, indic:ated their generalized, non-focal 
origin. The lack of convulsions during the appearance of the EEG hy-
persynchrony made this GHB-induced syndrome reminiscent of generalized, 
non-convulsant epilepsy as observed in man. This syndrome is, prefera-
bly, referred to as absence epilepsy (Gastaut, 1973), but it is also 
called "petit mal" because of its less impressive character as compared 
to the convulsive "grand mal"~ 
Absence epilepsy, as described by Marcus (1972), is characterized 
by short (5-30 s) interruptions of consciousness, during which general 
postural tone is relatively well preserved in most cases. During these 
periods, the patient is observed to stare, oblivious of stimuli intro-
duced into his environment. He also interrupts his ongoing activities. 
This interruption is relatively abrupt in onset and in cessation. The 
patient's awareness and motor activities return promptly at the end of 
the electrical discharge in the EEG. Memory is defective only for the 
period of the seizure. It is as though the patient, although physical-
ly present, is ''absent" with regard to his higher cortical functions 
for the brief period of the seizure. For this reason this form of gen-
eralized, non-convulsant epilepsy ~s called "absence epilepsy". Hinor 
motor phenomena usually accompany the absence seizure. Of these, the 
most characteristic are eyelid opening, eyelid myoclonus, and at times 
repetitive ocular movements. Myoclonus of face and repetitive chewing 
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may also occur. Some minor loss of postural tone in neck muscles may 
occur with dropping of the head onto the chest. Automatic movements 
involving the hands may occur; at times these movements are appropriate 
to the environmental situation. When examined more closely, it is 
found that the impairment of awareness, of response capacity, and of 
motor activity are relative phenomena occurring to variable degrees. 
Thus, patients are usually unaware of phrases or numbers which are pro-
vided as auditory or visual stimuli during the episode; some patient~ 
are aware of these same stimuli and can even repeat them during the 
episode or during questioning following the episode. Some patients are 
able to continue a familiar recitation during the absence seizure. 
Whether a response to a stimulus occurs during these brief seizures may 
in part depend on the intensity of the stimulus. and on the motivation 
and the past experience of the patient (Marcus, 1972). 
Besides these "typical n absences, associated with a generalized 3 
c/s spike-and-wave EEG pattern, brief losses of consciousness may ac-
company certain localized or "partial" epileptic seizures, principally 
of temporal lobe origin. These losses of consciousness present clini-
cally as absences (Gas taut, 1973). However, for various etiological, 
therapeutic and other reasons, they are not usually considered to be 
absences as such. Nevertheless, some authors continue to refer to them 
as "absences", qualified by an adjective denoting the region of origin 
(usually "temporal lobe absences"). This usage is not recommended 
(Gas taut, 1973). 
As to the "typical absences": it is very difficult, if not impos-
sible, to establish such short interruptions of consciousness and memo-
ry in animals. However, during the appearance of GHB-induced EEG hy-
persynchrony a behavioral pattern is observed which is reminiscent of 
the abrupt cessation and resumption of motor activity during absences 
in humans. 
The EEG during absences consists of characteristic 3/s spike-wave 
complexes. A similar pattern is induced by GHB in the cat (Snead et 
al., 1976). In the rat after GHB we observed EEG spikes alternating 
with one or more slow waves. This pattern was, however, less regular 
and possessed a slightly higher frequency than the classical human 
spike-and-wave EEG. The difficulty to induce this pattern in the rat 
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was also reported by other authors (McQueen and Hoodbury, 1975). 
Besides these phenomenological similarities between the effects of 
GHB and absence epilepsy, it was observed that the EEG hypersynchrony 
after GHB was antagonized by trimethadione, n-dipropylacetate, etho-
suximide and also amphetamine, drugs which proved to be effective in 
the treatment of absence epilepsy. Drugs effective against convulsive 
epilepsy, on the other hand, like diphenylhydantoin and mephenytoin, 
did not suppress the hypersynchrony. This points towards a pharmacolog-
ical resemblance between the GHB effect and absence epilepsy. 
The ability of GHB to induce a syndrome in animals which is remi-
niscent of absence epilepsy with regard to the EEG and the behavior as 
well as to its pharmacological properties is quite exceptional. Many 
artificially induced syndromes in several animal species, mimicking one 
or more aspects of absence seizures, have been proposed as models to 
study mechanisms underlying this type of epilepsy. However, all are 
imperfect. 
During insulinic hypoglycemia in the cat, absence-like behavior 
was observed, accompanied by a generalized 3/s spike-and-wave EEG 
(Waltregny, 1969). However, in this model convulsions also occurred, 
differentiating it from the non-convulsive absence epilepsy. Moreover, 
to our knowledge, no antiepileptic drugs were tested. 
Bilateral application of alumina cream, cobalt, pentylenetetrazol 
or conjugated estrogens to the cortex of cats and monkeys was found to 
induce spike-and-wave EEG patterns (Marcus, 1972). When conjugated 
estrogens were applied to the cortical anterior premotor area in the 
monkey, short staring spells, resembling absence seizures, were ob-
served , together with the spike-and-wave EEG (Marcus, 1972). These 
models, however, are of focal origin, and are, thus, essentially dif-
ferent from the generalized absence epilepsy in man. Horeover, the 
sensitivity of these models to specific anti-absence drugs has not been 
tested, with one exception: EEG patterns induced by bilateral cortical 
application of conjugated estrogens appeared to be antagonized specifi-
cally by anti-absence drugs, and were proposed as a suitable model for 
testing potential drugs of this type (Fowler and Julien, 1974). 
Systemic administration of various convulsant drugs in several an-
imal species was reported to induce spike-and-wave EEG patterns. These 
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drugs include pentylenetetrazol (Huot et al., 1973), fluoroacetate 
(Chenoweth and St.John, 1947) and hexafluorodiethyl ether (Krantz et 
al., 1957). However, the spike-and-wave EEG pattern induced by these 
compounds is accompanied by convulsive mvvements, in contrast to the 
non-convulsive absence epilepsy. On the other hand, it is important to 
note that the convulsive syndrome elicited by one of these drugs, pen-
tylenetetrazol, can be antagonized by several anti-absence drugs. 
As mentioned above, none of these models mimicks absence epilepsy 
~n the same measure as does the GHB-induced syndrome. Though the typi-
cal spike-and wave EEG pattern is elicited in the cat but not in the 
rat, the other effects of 200 mg/kg GHB in the rat, including the spe-
cific sensitivity to anti-absence drugs, make this syndrome one of the 
best matching animal models of absence epilepsy. Thus it might provide 
a useful model in studying the mechanisms underlying this type of epi-
lepsy. 
In view of the reported natural occurrence of GHB in mammalian 
brain (Roth and Giarman} 1970; Doherty et al., 1975 a), it is conceiv-
able that this compound plays a role in the etiology of absence epilep-
sy in man. In this context, the suggestion of Hirata et al. (1973) 
that GHB could be used for clinical EEG diagnosis is noteworthy. These 
authors were able to detect patients with organic brain disorders who 
did not show definite EEG abnormality on routine examination, but 
showed marked deviation from normal after activation of the EEG by GHB 
(Hirata et al., 1973). One could imagine that administration of GHB, 
in subthreshold doses, during EEG diagnosis, might enable patients 
suspected of absence epilepsy to be selected with more certainty. 
As suggested earlier, the G~--IB-induced EEG hyper synchrony might 
also be useful as a model to test the possible anti-absence efficacy of 
drugs. Though many animal models are used to test potential antiepi-
leptic drugs, no single model can give a reliable answer concerning the 
anti-absence specificity of the investigated compound (Naquet and 
Lanoir, 197 3) . 
The classical models for this purpose are convulsions induced by 
either intravenous or subcutaneous injection of pentylenetetrazol 
(Swinyard, 1969). As mentioned above, these seizures are antagonized 
by several anti-absence drugs. Conversely, it was suggested that 
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compounds counteracting pe.ntylenetetrazol seizures would be effective 
in the treatment of absence epilepsy (Jenney and Pfeiffer, 1956). At 
present, pentylenetetrazol convulsions are the most commonly used model 
to test potential anti-absence drugs (Swinyard, 1969). However, activ-
ity against penrylenetetrazol is not essential for, nor constantly pre-
dictive of, efficacy in the treatment of absence epilepsy. For exam-
ple, the anti-absence drug trimethadione is less effective against pen-
tylenetetrazol than phenobarbital, generally used in convulsive epilep-
sy (Millichap, 1969). Recently, Desmedt and co-workers (1976) distin-
guished different groups of drugs according to their action against 
certain components of pentylenetetrazol convulsions. This division in-
to groups correlated well with the antiepileptic profile of the drugs. 
However, notwithstanding their more accurate analysis, the authors con-
firmed the above conclusions of Millichap concerning the limited use-
fulness of pentylenetetrazol for testing anti-absence drugs (Desmedt et 
al., 1976). 
Another model of epilepsy, which promises to be useful in testing 
anti-absence drugs, is light-stimulation-induced convulsions in photo-
sensitive baboons of the species Papio papio (Woodbury, 1972). This 
suggestion was based on the inhibition of these seizures by several 
anti-absence drugs (Stark et al., 1970; Killam, 1976). The fact, how-
ever, that these seizures are also counteracted by diphenylhydantoin 
(Stark et al., 1970; Killam, 1976), a drug effective against convulsive 
epilepsy, decreases the specific value of this model in testing anti-
absence drugs. 
Another test model for potential anti-absence drugs based on light 
stimulation was proposed recently (Shearer et al., 1976). It employs 
photically evoked electrocortical afterdischarges in rats, which are 
significantly inhibited by the specific anti-absence drugs trimetha-
dione and n-dipropyl-acetate but not by diphenylhydantoin (Shearer et 
al., 1974; 1976). 
When mentioning these two functional models of absence epilepsy, 
both using responses elicited by photic stimulation, it is worthwhile 
emphasizing that GHB increased the amplitude and duration of cortical 
and subcortical potentials evoked by light stimulation in the cat 
(Kharkevich et al., 1971). This point of similarity between the effect 
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of GHB and both light stimulation-induced models is made more relevant 
by the fact that, in human absence patients, photosensitivity also 
exists and spike-and-wave patterns may be provoked by intermittent 
light stimulation (Bickford and Klass, 1969). Thus, in this respect 
also, some parallelism exists between the effects of GHB and absence 
epilepsy. 
Two other models for predicting efficacy of drugs against absence 
se~zures should be mentioned here. co 2-,vithdrawal seizures in rats and 
the response to repetitive stimulation in the spinal cord of cats, both 
models of generalized epilepsy, are inhibited by trimethadione, whereas 
diphenylhydantoin is ineffective and even enhances the first type of 
seizures (Woodbury, 1972). 
As no single model can provide a decisive answer concerning the 
anti-absence efficacy of a potential drug, it is necessary to use a 
combination of tests for screening new drugs. The specific sensitivity 
of GHB-induced EEG hypersynchrony to anti-absence drugs justifies its 
further evaluation as an additional model in the battery of tests for 
this type of drug. When used routinely, it might seem too laborious to 
implant electrodes into every rat to be used. On the other hand, how-
ever, these rats can be used several times. In the present experiments 
we used each rat for about 3 months in 8-10 sessions. Moreover, the 
rats can be used as their own control, excluding interindividual dif-
ferences. Thus, it is possible both to reduce the number of rats re-
quired and to increase the reliability of the results. 
9. 2. Behavioral sedation induced by GHB: sleep, anesthesia 
or epilepsy? 
For a long time since the discovery of the sedating effects of 
butyrate (Samson and Dahl, 1955; Samson et al., 1956; White and Samson, 
1956) and GHB (Jouany et al., 1960 a,b; Laborit et al., 1960), the 
induced behavioral states have been looked upon as 11 sleep 11 or "anesthe-
sia" (White and Samson, 1956; Jouany et al., 1960 a,b; Laborit et al., 
1960; Perez de la Mora and Tapia, 1970; Laborit, 1973). These conclu-
sions, however, were largely based on observation of the behavior, and 
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to a lesser extent on the increased amplitude of the EEG. More precise 
examination of the GHB-induced EEG revealed that it was different from 
patterns seen during physiological sleep or anesthesia (Benda et al., 
1960; Solway and Sadove, 1965). Instead, it was found to be similar to 
the hypersynchronous EEG patterns seen during epilepsy (Schneider et 
al., 1963; Winters and Spooner, 1965 a,b; 1966; Harcus et al., 1967). 
Moreover, higher doses of GHB (over 600 mg/kg) induced myoclonic jerks, 
and convulsions could be elicited by repetitive auditory stimulation 
(Winters and Spooner, 1965 a,b; Marcus et al., 1967; Osuide, 1972 b). 
This continuous drug-induced transition from a state of behavioral 
sedation via myoclonus to seizures was also observed after administra-
tion of the anesthetic agent ketamine (Ketalar(R)) and some other, but 
not all, anesthetics (Winters et al., 1969; 1972). It inspired Winters 
to develop a theory concerning a multidirectional continuum of anes-
thetic states (fig. 9.1 .), some represented by central nervous system 
(CNS) excitation and others by depression (Winters, 1976). According 
to this theory, the reticular activating system is influenced by all 
anesthetics; some inhibit its action (halothane, barbiturates; stage 
III) and some hyperexcite the system (nitrous oxide; stage IIC). Some 
agents traverse both excitation and depression (diethyl ether; stages 
I, II, III). Several compounds induce stage II and may proceed to 
further CNS excitation, manifested by seizures (GHB, ketamine, phen-
cyclidine, alpha-chloralose, trichloroethylene, enflurane). This 
implies that the effects of GHB are related to CNS excitation and con-
tradicts the interpretation of previous authors that the GHB-induced 
sedative state is due to CNS inhibition. Nevertheless, this GHB-
induced sedation can be viewed as anesthesia according to the function-
al, pragmatic definition of Winters (1976), stating that surgical 
anesthesia is "a stage induced by a drug that makes the subject rela-
tively unresponsive to painful stimuli, and amnestic". 
Notwithstanding the excitatory effect of GHB, our results show 
that this compound may also enhance physiological sleep. This, howev-
er, does not support the opinion of Laborit and others, saying that the 
sedative state induced by 500-1500 mg/kg GHB i.p. was identical to 
physiological sleep (Jouany et al., 1960 a,b), since the increased 
duration of SWS observed in our experiments was caused by lower doses 
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Fig. 9.1. Schematic representation of the stages of anesthesia. 
CNS excitation is implied above the awake level and CNS depression 
below. The cortical EEG (cat) representative of each stage is 
depicted (from Winters, 1976). 
(50-100 mg/kg) than those used by these authors. 
The influence of sleep stages on the susceptibility to generalized 
seizures has been the subject of many investigations and some review 
articles (Janz, 1962; Pompeiano, 1969; Passouant et al., 1975). The 
major epilepsies and tonic-clonic grand mal attacks are, in particular, 
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enhanced by SWS (Pompeiano, 1969; Pas sou ant et al., 1975). Absence 
episodes, in case they would occur during sleep, can not be distin-
guished behaviorally. The EEG pattern, characteristic of absence epi-
lepsy -3/s spike-wave complexes- however, was observed during var1ous 
sleep stages. These EEG phenomena were facilitated during PS (Sato et 
al., 1973; Passouant et al., 1975) and also during the transition from 
one sleep stage to another, at sleep onset and upon awakening 
(Passouant et al., 1975). 
It is possible that this relationship between absence epilepsy and 
PS plays a role in the mechanism of action of GHB, in view of the re-
ported induction of PS by GHB in cats (see 1. 1 .3.). Hmvever, since 
this induction of PS could not be confirmed by several other authors, 
even in the same species, such a connection remains entirely specula-
tive. 
9.3. GHB-induced EEG hypersynchrony: the mechanism of action 
An attempt was made to elucidate the neurotransmitter mechanisms 
underlying the induction, by GHB (200 mg/kg), of the syndrome reminis-
cent of absence epilepsy. To this purpose, the effects of several 
compounds on the duration of GHB-induced EEG hypersynchrony were mea-
sured. 
We aimed our efforts at two well-documented CNS actions of GHB: 
cessation of impulse flow in the dopaminergic nigrostriatal pathway and 
inhibition of GABA synthesis by GAD. 
In Chapter 5 we sho·wed that modulation of DA receptor stimulation 
did not influence the duration of GHB hypersynchrony, suggesting that 
the DA system plays no major role in this mechanism. This suggestion 
was supported by experiments with HA-966, a synthetic compound similar 
to GHB in many respects. HA-966 antagonizes nigrostriatal neurotrans-
mission, induces synchronization of the EEG and enhances the duration 
of GHB-induced EEG hypersynchrony, as was shown in Chapter 7. The 
synchronizing effect of HA-966 appeared to be unchanged in rats with an 
electrolytically lesioned substantia nigra compacta. This indicates 
that the integrity of the nigrostriatal system is not necessary for the 
90 
EEG effects of HA-966. Because of the similarity between GHB and 
HA-966, these results might support our previous suggestion, saying 
that DA plays no major role in the generation of hyper synchrony by GHB. 
In the experiments described in Chapter 6, GHB was administered to 
rats pretreated with AOAA. The results were interpreted in view of the 
twofold dual mechanism of AOAA. This compound counteracted the effect 
of GHB, but only in a dose inhibiting GABA breakdown and not its syn-
thesis, and only 6 h after administration of AOAA, when the antiepilep-
tic activity of this compound is maximally related to the GABA system 
(Wood and Peesker, 1976). These results point towards an involvement of 
GABA metabolism in the EEG effects of GHB. This conclusion is support-
ed by the findings that both HA-966 and DPI prolonged the action of GHB 
and that DPA inhibited it. For both former compounds, indications 
exist that they might inhibit GAD and thus act synergistically with 
GHB, whereas DPA inhibits GABA breakdown, abrogating GAD inhibition. 
Additional experiments are necessary before final conclusions can 
be drawn concerning the mechanism of action of GHB. It is possible 
that, besides inhibition of GABA synthesis, other neurotransmitter 
mechanisms may also play a role. The reported inhibitory action of 
amphetamine on the effect of GHB was suggested to be a noradrenergic 
effect. Moreover, the possibility remains that two different DA sys-
tems are involved. Such a system, in turn, might interact with other 
neurotransmitters. 
The involvement of subcortical brain structures in the generation 
of the EEG and behavioral effects of GHB has been studied only scarce-
ly. Thus the way of action of GHB on the anatomical level is as yet 
unknown. Electrically evoked seizures in the hippocampus and amygdala 
of cats were prolonged by GHB (Drakontides et al., 1962), which might 
point at a role for these limbic structures in the propagation of GHB 
hyper synchrony. 
The thalamus might also be of importance, since the thalamo-
cortical recruiting response in cats was increased by GHB (Drakontides 
et al., 1962), as was the amplitude of the thalamic response upon sci-
atic nerve stimulation (Kharkevich et al., 1971). In this context it 
is noteworthy that a 3 c/s spike-and-wave pattern could be produced on 
stimulation of the midline nuclei or of the intralaminar system of the 
91 
thalamus (Jasper and Droogleever-Fortuyn, 1946). It \vas also demon-
strated that stimulation of this area in unanesthetized animals pro-
duced an arrest of movement, reproducing the behavioral components of 
absences (Hunter and Jasper, 1949). Thus, a parallel exists between 
thalamic stimulation, inducing certain phenomena characteristic of ab-
sence epilepsy, and the effects of GHB, resembling absence epilepsy and 
enhancing the response to thalamic stimulation. This might suggest a 
role for the activity of certain thalamic nuclei in the generation of 
the effects of GHB. Further experimental evidence, however, is re-
quired to prove this suggestion. 
In particular, it will be of interest to investigate the effects 
of GHB, when administered into discrete brain areas, upon single and 
multiple unit EEG registrations from various subcortical regions. This 
approach might, eventually, contribute to the understanding of the 
pathophysiological mechanisms underlying absence epilepsy. 
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SUMMARY 
The effects of sodium-gamma-hydroxybutyrate (GHB) on the cortical 
electroencephalogram (EEG) and behavior of the rat and the underlying 
neuronal mechanisms have been investigated. 
In chapter 1 a review is presented of the literature concernlng 
GHB and some related COillpounds, especially garnma-butyrolactone (GBL) 
and 1-hydroxy-3-amino-pyrrolidone-2 (HA-966). The state of behavioral 
sedation, induced by GHB and GBL, has been interpreted differently by 
several authors. Initially, this state was considered as 11 sleep 11 or 
11 anesthesia". Y.Tien administered in low doses (50-100 mg/kg) these 
compounds were reported to induce paradoxical sleep (PS) in cats. 
Registration of the EEG lTI animals and man after administration of 
higher doses of GHB and GEL (400-700 mg/kg), however, showed a high 
amplitude. Several authors considered this as a confirmation of the 
assumed induction of slow wave sleep (SWS) by these compounds. Closer 
observation of the amplitude and pattern of the EEG, however, brought 
to light a similarity bet\veen this phenomenon and epilepsy, though no 
spontaneous convulsions were observed, and myoclonic jerks only appear-
ed after higher doses of botl1 compounds. 
These conflicting reports prompted the present investigation into 
the effects of GHB, in relatively low doses (12.5-200 mg/kg), on corti-
cal EEG and behavior in the rat, with special reference to sleep and 
epileptoid phenomena. 
The influence of GHB (12.5-100 mg/kg) on sleep stages 1n the rat 
is described in Chapter 2. Neither of these doses changed the normal 
EEG patterns. The lowest doses of GHB (12.5-25 mg/kg) did not modify 
the duration of the awake state, SWS or PS, as measured by combined 
examination of EEG and electromyogram (EMG). 50 and 100 mg/kg GHB, how-
ever, prolonged the duration of SWS by up to 4 h after administration, 
but the time spent in PS remained unchanged. This confirmed the sug-
gestion of other authors that the reported induction of PS by GHB in 
cats is not a general phenomenon in all mammals. It is also reported 
that, during PS, a 6-8 Hz (theta) rhythm appears in the EEG of the rat 
and can be registered in several regions of the cortex. 
The effects of a slightly higher dose of GHB, 200 mg/kg, are de-
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cribed in Chapter 3. The induced EEG possesses a higher amplitude than 
the normal EEG. Its pattern was also different and contained high am-
plitude spikes, separated by one or more slow waves. These high ampli-
tude or "hypersynchronous 11 phenomena, reminiscent of epilepsy in man or 
convulsive disorders in animals, appeared simultaneously on both hemi-
spheres. No convulsions or other jerky movements were observed. This 
pointed towards a similarity between the effects of GHB and generalizedJ 
non-convulsive epilepsy or absence (petit mal) epilepsy. During the hy-
persynchrony, the rats were motionless, which was suggested to be a mo-
tor analogue of absences. The 3/s spike-and-wave EEG, typical of ab-
sence epilepsy, was not induced by GHB in the rat, contrary to the cat. 
The suggested resemblance of the effects of 200 mg/kg GHB to ab-
sence epilepsy was strengthened by the influence of antiepileptic drugs 
on these phenomena, as presented in Chapter 4. Pretreatment of rats 
with the specific anti-absence agents ethosuximide, trimethadione and 
n-dipropylacetate antagonized the effects of a subsequent GHB injec-
tion. Diphenylhydantoin and mephenytoin on the other hand, drugs ef-
fective against convulsive epilepsy, did not counteract the GHB-induced 
EEG hypersynchrony. In view of these results it was proposed that this 
syndrome might be used as an animal model for screening potential anti-
absence drugs. 
In the following chapters an attempt was made to identify the neu-
rotransmitter systems underlying the effects of GHB on the EEG. The 
most documented effect of GHB at the level of neurotransmission, name-
ly inhibition of the impulse flow in the nigrostriatal dopaminergic 
(DA) system, was examined in this respect, as discussed in Chapter 5. 
It appeared that both specific DA receptor agonists apomorphine and 
piribedil, and the DA receptor blocker haloperidol, did not influence 
the duration of GHB-induced hypersynchrony. This argues against a role 
for the cessation of nigrostriatal impulse flow in the EEG effects of 
GHB. 
Since GHB has been reported to block gamma-aminobutyric acid (GABA) 
synthesis, an investigation into a possible relation between the hyper-
synchronizing effect of GHB and the putative neurotransmitter GABA is 
described in Chapter 6. Amino-oxyacetic acid (AOAA) at a suitable dosP 
and with a suitable pretreatment time, antagonized the duration of GHB 
94 
hypersynchrony. This effect ~vas connected ~vith the reported inhibi-
tion of GABA breakdown by AOAA under these conditions, an action which 
is also responsible for the antiepileptic activity of this ccmpound. 
Thus, it was concluded that the hypersynchronizing effect of GHB is 
most probably related to inhibition of GABAergic neurotransmission. 
In Chapter 7 a synergistic influence of HA-966 on the duration of 
GHB hypersynchrony was reported. In view of the many similarities be-
tween these compounds, it was suggested that a canmon mechanism of 
action might exist for both GHB and HA-966. 
Impairment of the nigrostriatal DA pathway by electrolytic abla-
tion of the Substantia n1gra did not influence the amplitude of the 
EEG or the desynchronization upon acoustic stimulation. Neither did 
it modulate the EEG synchronizing effect of HA-966. These results, 
reported in Chapter 8, were interpreted as supporting evidence for the 
conclusion that the nigrostriatal DA system does not play a major role 
in the EEG effects of either HA-966 or GHB. 
In Chapter 9 the practical consequences of the present results 
are discussed. It ~vas emphasized that GHB-induced EEG hypersynchrony 
might serve as an additional model for testing the anti-absence effi-
cacy of new drugs. Moreover, as GHB occurs naturally in the brains of 
several mammalian species, a possible role for GHB in the etiology of 
absence epilepsy was suggested. 
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SAME NV ATTING 
In dit proefschrift is een onderzoek beschreven naar de invloed 
van gamma-hydroxybutyraat (GHB) op het electroencephalogram (EEG) en op 
het gedrag van de rat, en naar de neuronale mechanismen die daaraan ten 
grondslag liggen. 
Hoofdstuk 1 geeft een overzicht van de literatuur over GHB en een 
aantal verwunte stoffen, waaronder gamma-butyrolacton (GEL) en 1-hydro-
xy-3amino-pyrrolidon-2 (HA-966). Ret bijzonder rustige gedrag, veroor-
zaakt door GHB en GBL is door een aantal onderzoekers verschillend uit-
gelegd. Aanvankelijk werd deze toe stand beschouwd als 11 slaap" of 
"anesthesie". Toegediend in een lage dosering (50-100 mg/kg) bij kat-
ten, bleken deze stoffen paradoxale slaap (PS) te veroorzaken. Na toe-
diening van GHB en GBL in hogere doses (400-700 mg/kg) bij proefdieren 
en mensen vertoonde het EEG echter een hoge amplitude. Verscheidene 
auteurs beschouwden dit als een bevestiging van hun veronderstelling 
dat deze stoffen rustige slaap of "slow wave sleep 11 (SWS) veroorzaken. 
Bij nadere beschouwing van amplitude en patroon van het EEG bleken er 
echter avereenkomsten te bestaan tussen dit verschijnsel en epilepsie 
C1vallende ziekte 11 ), alhoewel er geen spontane convulsies (stuiptrek-
kingen) optraden en verspreide spiertrekkingen alleen waargenomen wer-
den na toediening van veel hogere doses van deze stoffen. 
Deze elkaar tegensprekende resultaten waren de aanleiding voor bet 
onderhavige onderzoek naar de invloed van GHB, in lage doseringen 
(12.5-200 mg/kg), op EEG en gedrag van de rat. Daarbij werd bijzondere 
aandacht besteed aan slaap en op epilepsie lijkende verschijselen. 
De invloed van GHB (12.5-100 mg/kg) op slaaptoestanden in de rat 
werd beschreven in H0ofdstuk 2. Geen van deze doseringen veranderde de 
normale EEG patronen. De laagste doseringen (12.5-25 mg/kg) brachten 
geen wijziging in de duur van de waaktoestand, SWS of PS, gemeten met 
behulp van een combinatie van EEG en electromyogram. Toed iening van 50 
of 100 mg/kg GHB verlengde daarentegen de tijdsduur doorgebracht in 
SWS, maar de duur van PS bleef onveranderd. Dit bevestigde de veron-
derstelling van andere auteurs dat de gevonden toename van PS, onder 
invloed van GHB ln katten, geen algemeen verschijnsel is in alle zoog-
dieren. Daarnaast werd aangetoond dat, tijdens PS, een 11 theta11 ritme 
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(6-8 Hz) 1n het EEG verschijnt en opgevangen kan '>vorden op meerdere 
plaatsen op de hersenschors. 
De uitwerking van een iets hogere dosis GHB (200 mg/kg) is be-
schreven in Hoofdstuk 3. Het veroorzaakte EEG heeft een hogere ampli-
tude dan normaal. Het patroon was oak verschillend en vertoonde hoge 
pieken, gescheiden door een of meer langzame golven. Deze EEG ver-
schijnselen met een hoge amplitude, ook wel hypersynchronie genoemd, 
doen denken aan epilepsie in de mens of convulsieve verschijnselen in 
proefdieren. De hypersynchronie verscheen gelijktijdig aan beide zij-
den van de hersenschors. Convulsies of verspreide spiertrekkingen wer-
den werden niet waargenomen. Dit wees op een gelijkenis tussen de ef-
fecten van GHB en gegeneraliseerde, niet-convulsieve epilepsie, oak wel 
petit-mal of absence epilepsie genoemd. Tijdens de hypersynchronie '>va-
ren de ratten bewegingloos, hetgeen was voorgesteld als een mogelijk 
analogon van absences. Het EEG met 3 piek-golf complexen per seconde 
werd niet veroorzaakt door GHB in de rat, dit in tegenstelling tot de 
kat. 
De veronderstelde overeenkomst tussen de effecten van 200 mg/kg 
GHB en absence epilepsie werd versterkt door de invloed van anti-epi-
leptische geneesmiddelen op deze verschijnselen, beschreven in Hoofd-
stuk 4. Voorbehandeling van ratten met de specifieke anti-absence 
stoffen ethosuximide, trimethadion en n-dipropylacetaat deed de invloed 
van een daaropvolgende GHB-toediening teniet. Diphenylhydantoine en 
mephenytolne daarentegen, stoffen die gebruikt worden in de behandeling 
van convulsieve vormen van epilepsie, gingen de door GHB veroorzaakte 
EEG hypersynchronie niet tegen. Gezien deze resultaten werd geopperd 
dat het EEG-effect van GHB gebruikt zou kunnen worden als een diermodel 
voor het schiften van nieuwe geneesmiddelen op hun mogelijke werking 
tegen absence epilepsie. 
In de volgende hoofdstukken werd gepoogd .vast te stellen welke 
neurotransmitter-systemen ten grondslag liggen aan de EEG-effecten van 
GHB. Het meest onderzochte effect van GHB op neurotransmissieniveau, 
namelijk het remmen van de prikkeloverdracht in het nigro-striatale 
dopaminerge (DA) systeem, werd centraal gesteld in dit verband, zoals 
beschreven in Hoofdstuk 5. 
Het bleek dat zowel de specifieke DA receptor agonisten apomorfine en 
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piribedil, als de DA receptor blokker haloperidol, de duur van de GHB-
hypersynchronie niet belnvloedden. Dit pleit tegen een rol voor de 
rernming van nigrostriatale prikkeloverdracht in het EEG effect van GHB. 
Gezien de aanwijzingen dat GHB de synthese van gamrna-arninoboter-
zuur (GABA) stillegt, werd gezocht naar een mogelijk verband tussen het 
hypersynchroniserende effect van GHB en GABA, waarvan verondersteld 
wordt dat het een neurotransmitter is. De resultaten werden beschreven 
in Hoofdstuk 6. Amino-oxy-azijnzuur (AOAA), in de juiste dosis en met 
een geschikte voorbehandelingstijd, verminderde de duur van de GHB-
hypersynchronie. Dit effect werd in verband gebracht met de remming 
van de afbraak van GABA door AOAA onder gelijke omstandigheden. Die-
zelfde remming wordt ook verantwoordelijk geacht voor de anti-epilepti-
sche werking van deze stof. De resultaten leidden tot de gevolgtrek-
king dat de GHB hypersynchronie hoogst waarschijnlijk in verband staat 
met remming van de prikkeloverdracht in een GABA-systeem. 
In Hoofd s tuk 7 werd ver slag ged aan van een syner gis tis che inv loed 
van HA-966 op de duur van de GHB hypersynchronie. Gezien de vele over-
eenkomsten tussen beide stoffen werd geopperd dat er mogelijk eenzelfde 
werkingsmechanisme bestaat voor GHB en HA-966. 
Ontregeling van de nigrostriatale DA baan door electrolytische 
vernietiging van de Substantia nigra had geen invloed op de amplitude 
van het EEG, noch op de amplitudeverlaging door geluidsprikkeling. 
Bovendien werd ook de EEG hypersynchronie na toediening van HA-966 niet 
beinvloed door zo'n letsel. Deze resultaten, beschreven in Hoofdstuk 
8, werden beschouwd als een ondersteuning van de veronderstelling dat 
bet nigrostriatale DA systeem geen belangrijke rol speelt in de beln-
vloeding van het EEG door zowel HA-966 als GHB. 
In Hoofdstuk 9 werd de praktische betekenis van de resultaten be-
sproken. De EEG hypersynchroni~ zou van nut kunnen zijn als een toe-
voeging aan de serie tests die bebruikt worden voor het onderzoeken van 
mogelijke nieuwe geneesmiddelen voor absence epilepsy. Gezien het feit 
dat GHB normaal voorkomt in de hersenen van verscheidene zoogdiersoor-
ten, werd bovend ien de mage 1 ijkheid geopperd d at G HB een ro 1 speel t in 
het ontstaan van absence epilepsie. 
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